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THE EPIDEMIC OF ANTIBIOTIC RESISTANCE: A LEGAL REMEDY TO
ERADICATE THE "BUGS" IN THE TREATMENT OF INFECTIOUS DISEASES
There are some remedies worse than the disease.
-Publilius Syrus'
I. INTRODUCTION
For nearly three centuries, medieval Europe was stricken by the devastat-
ing forces of the Black Death.2 The mysterious infections caused by the plague
harbored the ability to destroy all living organisms in their path.' The victims were
marked by symptoms such as "gangrenous inflammation of the throat and lungs,
violent pains in the chest, vomiting and spitting of blood, tumors on the groin and
neck, and purple spots caused by subcutaneous hemorrhages."' The epidemic
killed about one-third the population of England and dramatically altered the
social, political, and economical life of its survivors.' The destructive power of
1. THE NEW INTERNATIONAL DICTIONARY OF QUOTATIONS 184 (2d ed. 1993).
2. See CHARLES MULLETr, THE BUBONIC PLAGUR AND ENGLAND: AN ESSAY IN THE HISTORY
OF PREVENTATIVE MEDICINE, 1 (1956). The author notes that "no epidemic has been assessed
on the same scale as the Black Death because none has had equal impact. Id. at 2. 'The mor-
tality of the sixteenth and seventeenth centuries owed much to the greater movement of peo-
ple within the country and immigration from abroad." Id. The plague of course varied in type
and in virulence, it did not stand alone or follow a certain pattern. Id. at 8. "It was often the
inseparable, ferocious companion of typhus, and both were reinforced by dysentary, diphteria,
cholera, smallpox, and typhoid fever." Id. at 8-9
3. Id. at 39. "In the fifteenth century, several poets saw sudden death lurking around every
corner." Id. 'This world was a thoroughfare of woe; Death spared none but summoned all;
sickness was his beadle." Id. "Panic in England undoubtedly was, for the entire population
lived in fear of the giant who spared neither proud knights, lovely ladies, sturdy peasants, nor
pious priests."Id. at 40." The Black Death itself everywhere produced the most diverse
effects." Id. at 15. Its horrible mortality encouraged dissipation, persecution, and indifference.
Id. "A hectic and hysterical disregard for moral standards, reaching to excessive sexuality and
cannibalism, manifested the disintegrating blight on European civilization." Id.
4. Id. at 14. "A mild plague, characterized by swelling in the armpits or groin, some tem-
perature with a duration of ten to twenty days, left the general health largely unimpaired and
permitted the victim to go about as usual." Id. at 11 n. 14. "In the severe variety the early symp-
toms resembled those of plague: the patient became distracted, staggered about, suffered from
severe headaches, thirst, and general pain." Id. "His eyes became red and turbid, his tongue
swollen, dry, and fissured, sometimes black, sometimes white." Id. "Vomiting, fever, coma,
and generally obstinate constipation" were other symptoms. Id.
5. Id. at 14. 'The plague periodically attacked large sections of Europe for at least four
hundred years, and although its mortality, extent, and influence probably never again equaled
those of the mid-fourteenth century, it often reached spectacular figures and revolutionized life
in limited areas." Id. "In popular imagination, it was a man mounted on a big black horse, or
a giant striding along with his head far above the houses." Id. at 16. '"errific confusion
1
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the Black Death prompted governmental action and the development of preven-
tative medicine.'
In today's society, the unprecedented rise in infectious disease mortality,
elicits a red alert to our lawmakers to stem the burgeoning tide of antibiotic resis-
tance.7 "Without a doubt, diseases as yet unknown, but with the potential to be the
AIDS of tomorrow, lurk in the shadows."8 The batttle is staged: Man vs. Microbe,
in a quest for medical supremacy.' Can we ambush the black horse of death before
it is too late?
Since the discovery of penicillin in 1928, antibiotics have effectuated
rapid cures for many potentially fatal diseases."0 But, the endless miracles attrib-
uted to these drugs has also led to their misuse and overuse. Due to the wide-
spread application of antibiotics, bacteria have devised the cunning ability to out-
markedproperty titles, especially since the plague often carried off the last of the line." Id. at
24. "Lords of manors enjoyed a brief prosperity by the escheat of much property, but the imme-
diate advent of low prices through fear of death, shortage of labor, and plentiful crops soon
changed that." Id.
6. Id. at 22. "Since the problem of disease coincided with the problem of survival, the
epidemic of 1349 and its recurrent manifestations drove home the necessity for governmental
action." Id. "In the thirteenth century, public officials began to consider sanitation problems
seriously." Id. at 30. "They commanded the cleaning of town ditches and streets and carting
away of filth." Id. "One ordinance sought to keep swine off the streets; another expected every
man to clean the street in front of his tenement; a third provided for a sweeper to keep the
London streets free from litter." Id. Infected individuals were quarantined and houses were
marked, dogs were killed, and sanctions were enforced. Id. at 68-70. The municipal councils
established various rules governing the segregation of infected individuals and the occupancy
limitations; dwellings were limited to a single family unit. Id. at 70.
7. See Kathy Sheridan, The Day of the Super Bug, WORLD PREss REVIEW, Apr. 1991, at
40. The author notes that "fifty years ago, antibiotics were hailed as miracle drugs, 'magic bul-
lets' in the war against once-deadly bacterial infections such as pneumonia, tuberculosis, and
meningitis. For a few decades, it seemed no one would have to die of pneumonia or tubercu-
losis again. But then the bugs began to bite back. Using barely believable powers of mutation,
they began transforming themselves into doomsday super-bugs resistant to some, or even all,
types of antibiotics." Id.
8. Id. See also LAURIE GARRETr, THE COMING PLAGUE, 431 (1994). "We're running out
of bullets for dealing with a number of these infections...patients are dying because we no
longer in many cases have antibiotics that work." (quoting Joshua Lederberg, Nobel laurate).
9. See Sheridan supra note 7 at 40. The author comments on the problem of antibiotic
resistance: "The resistant organisms that are being produced are a whole new generation of
organisms.. .This resistance problem is one that I think is going to be a major plague for the
coming century." (quoting Ralph Henderson, WHO's assistant director-general). Id.
10. See STUART B. LEVY, M.D., THE ANTIBIOTIC PARADOX: HOW MIRACLE DRGS ARE
DESTROYING THE MIRACLE 6 (1992). The author notes that Alexander Fleming , coming back
from a weekend vacation, went through his usual routine of looking at some of the old agar
plates, and noticed the colonies of the common skin organism Staphylococcus had lysed seem-
ingly by the product of a mold growing nearby. Id. at 34. This Penicillium mold produced a
substance capable of bacterial cell wall lysis. Id. at 36. Alexander Fleming called this sub-
stance penicillin. Id. at 37. "Penicillin earned the accolade miracle drug because of its unique
[VOL. 30:4
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smart the enemy." As a result, many horrific diseases, once thought eradicated,
have resurrected to impose a significant health threat. 2 The evolution of antibiot-
ic resistance, whereby bacteria instinctively fight back, coupled with the inade-
quacy of new antibiotics on the test market mandates heightened concern for a
plausible "superbug" epidemic. 3
and rapid control of infectious bacteria that, before its discovery, had been fully expected to
kill the patient." Id. at 6. "Penicillin clearly symbolized our ability to outwit and control the
microbial world. Id. at 7. However, the drug was not man-made, but a product of molds." Id.
"For such naturally occurring substances that killed bacteria, the term "antibiotic" was
coined." Id. "Small amounts of penicillin cured blood-borne infections, pneumonia, and open
skin wounds." Id at 6. The author notes that Howard Florey is credited with producing peni-
cillin and demonstrating the drug's success in therapy in the U.S. in the 1940's. Id. at 5.
I1. See generally S.G. Jenkins, Mechanisms of Bacterial Antibiotic Resistance, NEW
HORIZ, Aug. 1996. The author describes some examples of how bacteria evade antibiotics. Id.
Specific mechanisms of resistance include reductions in cell-wall membrane permeability,
alterations of antimicrobial agent target sites, enzymatic inactivation of antibiotics, and devel-
opment of by-pass pathways around antimicrobial targets. Id. The author notes that bacteria
have evolved and developed resistance to all available antibiotics to a greater or lesser degree.
Id. See also Ron Gasbarro, Combating Growing Bacterial Antibiotic Resistance, AMERICAN
DRUGGIST, Feb. 1996, at 49. The author comments that both France and Spain have allowed
the over-the-counter (OTC) sale of penicillin, thus encouraging their unlimited and, in the
absence of medical supervision, improper use. Id. See also LEVY, supra note 10, at 107. The
author notes that in many parts of the world, such as Mexico, the Caribbean, South America,
and Southeast Asia, antibiotics can be obtained over-the-counter in pharmacies. Id. OTC avail-
ability generates a laissez-faire attitude toward medicines that leads to antibiotic misuse. Id.
12. See Gasbarro, supra note 11, at 49. The author comments that human diseases thought
to be under control are returning to wreak havoc. Id. The author mentions tuberculosis, dysen-
tery, and malaria as examples of diseases once thought to be eradicated which have been
restored. Id.
13. See LEVY, supra note 10, at 97. The author remarks that "given enough antibiotic use
and its consequent selection of resistant strains, resistance increases and rears a foreboding and
Hydralike head.. .with time, we see the creation of micro-organisms resistant, not to just one
drug, but to multiple drugs." Id. "It is the multiply resistant bacteria appearing in different dis-
eases and ecological settings that truly threaten our ability to treat infections successfully
today." Id. Even amidst the optimism from the successes of penicillin, hovered words of cau-
tion. Id. Alexander Fleming, who discovered the drug, warned in a 1945 interview that misuse
of penicillin could lead to the selection and propagation of mutant forms of bacteria resistant
to the drug. Id. Fleming had derived such mutant bacteria in the laboratory by growing sus-
ceptible bacterial strains in increasingly higher amounts of penicillin, starting with very small
amount of the drug. Id. The mutant bacteria altered their cells walls to be less permeable to
the drug. Id. Fleming, hoping to avoid producing these mutants in patients during therapy,
spoke out for complete courses of treatment. Id. Furthermore, since Fleming believed the
problem would escalate when penicillin became available in oral form, he warned the medical
world:
The greatest possibility of evil in self-medication is the use of too small doses
so that instead of clearing up infection, the microbes are educated to resist peni-
cillin and a host of penicillin-fast organisms is bred out which can be passed to
other individuals and from them others until they reach someone who gets a sep-
ticemia or a pneumonia which penicillin cannot save.
3
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When cough and cold season hits, antibiotics are dispensed in the mil-
lions.'4 In about half of these cases, the course of therapy is considered inappro-
priate. I Most patients and physicians are unaware of the harmful side effects that
may result from the misuse or overuse of antibiotics.'6 Furthermore, most patients
envision an antibiotic as a "cure-all" and physicians, in order to maintain cus-
tomer loyalty, will succumb to the patient's demands.'7 As a result, millions of
people are unnecessarily exposed to a whole array of antibiotics which enhances
bacteria's ability to evade destruction. 8
Despite historical predictions that infectious diseases would remain har-
nessed in the confines of medical technology, numerous recent events have
demonstrated the reemergence of evasive "bugs".'9 With society becoming more
mobile and travel abroad becoming more popular, the possibility of a Black Death
Id. The author regards these early words of Alexander Fleming as a historic prediction, the
magnitude of which has yet to be seen. Id. See also Gasbarro, supra note 11. Between 1987
and 1992, the prevalence of resistance to penicillin increased more than 60 times. Id. Between
1989 and 1993, hospital-acquired vancomycin resistant enterococci increased about 20 fold.
Id.
14. Id. The author notes that about 150 million courses of antibiotics are prescribed in the
United States each year. Id. See also Linda F. McCaig & James M. Hughes, Trends in
Antimicrobial Drug Prescribing Among Office-Based Physicians in the United States, 273
JAMA 214 (1995) (noting that in 1980, 1985, 1989, and 1992, antimicrobial agents were the
second leading therapeutic category of drugs, behind drugs active on the central nervous sys-
tem, prescribed by office based physicians in the United States).
15. See Gasbarro, supra note ,at 49. The author notes that of the 150 million prescriptions
for antibiotics each year, 50 percent of these are considered inappropriate for reasons from
incorrect empirical prescribing to overenthusiastic prophylactic use. Id.
16. See LEVY, supra note 10, at 105. The author comments on antibiotics stating:
Their introduction in the 1940's totally revolutionized the treatment of human
infections, and the successes of antibiotics continue to prompt their immediate use
when an infectious bacterial cause is suspected. The myth of the so-called "mira-
cle drugs" persists today, however, as people unthinkingly demand antibiotics for
ailments for which these agents have no value. In turn, their effectiveness is often
diminished, tarnishing their reputations and putting us at risk from unresponding
infection by drug resistant forms of bacteria.
Id.
17. Id. at 208. Many people envision the word antibiotic to mean a drug that will cure dis-
eases of all kinds. Id. For instance, the average patient will seek an antibiotic for viral condi-
tions such as the flu. Id. See also McCaig & Hughes, supra note 14, at 214 (noting that when
a patient expected an antibiotic, more often than not, he got one).
18. See LEVY, supra note 10, at 215. The unnecessary and inappropriate use of antibiotics
adds an economic burden to the health care system. Id. Given sufficient time and appropriate
circumstances, there is a strong association between the magnitude of use and the emergence
and spread of antimicrobial resistant strains. Id. at 218. The potential benefit to the patient who
receives treatment with an antimicrobial drug must be weighed against the public health risk
for the emergence of resistant organisms. Id.
19. See Robert W. Pinner et al., Trends in Infectious Disease Mortality in the United States,
275 JAMAI89 (1996). The authors remark that a previously unrecognized Hantavirus caused
[VOL. 30:4
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landing in the United States is a risk worth considering. 20
Although there are several medical approaches2 aimed at alleviating the
strain of bacterial resistance, their effects have been negligible.22 For example, the
pharmaceutical industry is pursuing the development of new antibiotics to fight
resistant strains, but the delayed arrival of reinforcement troops would be futile if
a sudden attack would commence. Therefore, in order to adequately address the
resistance problem, communication among health care participants and judicious
management of antibiotics should formulate the benchmark of any remedial
efforts. 2
an outbreak of fatal respiratory illness in the American Southwest in 1993. Id. Contamination
of a public water supply with the parasite Cryptosporidium was responsible for an outbreak
that caused more than 400,000 cases of diarrhea and resulted in more than 4,000 hospitaliza-
tions in Milwaukee, Wisconsin. Id. The recent outbreak of Ebola hemorrhagic fever in Zaire,
which resulted in than 296 cases, with a case-fatality rate of 79 percent, and the outbreak of
plague in India in 1994 raised questions about the importation of these diseases into the United
States. Id.
20. See Barbara E. Mintz et al., Reported Cholera in the United States, 1992-1994: a
Reflection of Global Changes in Cholera Epidemiology, 276 JAMA 307 (1996). The authors
note that outbreaks of cholera affecting 75 passengers on an airplane from Latin America and
5 passengers on a cruise liner from Southeast Asia accounted for 50 percent of the cases of
cholera in the United States. Id. See also Charles Henderson, Infectious Diseases Kill over 17
Million People a Year, AIDS WEEKLY PLUS, June 3, 1996, at 22. "[W]e are standing on the
brink of a global crisis in infectious diseases.. .no country is safe from them. No country can
any longer afford to ignore their threat." Id. (quoting Dr. Hiroshi Makajima, WHo). In addition,
the authors note that antibiotics used against many diseases are "rapidly losing their effective-
ness as bacteria and other microbes develop resistance to them." Id.
21. See S.K. Obaro et al., The Pneumoncoccal Problem, 312 BMJ 1521 (1996). The
authors note that Streptococcus pneumonia has always been a clinically significant cause of
morbidity and mortality but never more so than now because of the emergence of strains resis-
tant to many antibiotics. Id. at 1527. Furthermore, one approach to this problem is to improve
host protective immunity to the organism by immunization. Id. Although, current vaccines
have a good safety record, they lack efficacy. Id.
22. See Leslie Alan Horvitz, It's a War to Restore Antibiotics, INSIGHT ON THE NEWS, Mar
18, 1996, at 38. The author regards the medical approaches to the resistance problem to be too
little too late. Id. In addition, the availability and success rate of vaccinations has shown not to
make a substantial difference in the mortality rate from infectious diseases. Id.
23. Id. "A once formidable arsenal of antibiotics has become the medical equivalent of
blunderbusses and Gatling guns." Id. "During the last 12 years, the mortality rate from infec-
tious diseases has risen 58 percent." Id. "Many of us feel that the way to get back at the resis-
tance problem is to get a totally new class of antibiotics.. .and, in fact several pharmaceutical
companies are attempting to do just that, but they have a great deal of catching up to do." Id.
at 39 (quoting George Miller, head of preclinical infectious disease research at the Schering-
Plough Research Institute in Kenilworth, N.J.). Furthermore, "there have been no new drugs
for the last 2 years...all the ones that have been done in the nineties are modifications of exist-
ing drugs-so whatever resistance developed in the old ones is carrying over to the new
ones.. .the best solution : exercise more prudence when it comes to prescribing antibiotics." Id.
at 42 (quoting Stuart Levy, Professor at Boston's Tufts University).
24. See Robert M. Hamm et al., Antibiotics and Respiratory Infections: Are Patients More
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Even though some hospitals have initiated programs aimed at curbing
inappropriate antibiotic use, present day circumstances warrant a comprehensive
approach to the pending epidemic.15 In an era where managed care organizations
are prevalent and the crux of health care takes place in the community, the oppor-
tunity exists for a legal remedy to halt the progression of a possible "superbug"
tyranny. 6 This article sets forth the Antibiotic Resistance Epidemic in Part 11.27
Parts III and IV discuss the causative agents while emphasizing the need for a reg-
ulatory attack to the problem. 8 The remainder of this article concentrates on a
proposal to extend Ohio statutory regulations to address the antibiotic resistance
problem in Parts V and VI, 9 while dissecting the oppositions concerns about the
prohibitive measure in Part VII2
II. ANTIBIOTIC RESISTANCE EPIDEMIC
Many of the killer diseases of the past such as tuberculosis, typhoid fever,
diphtheria, and pneumonia have returned to wreak havoc as bacteria are increas-
ingly resistant to antibiotics.' In the last 10 years, the frequency and spectrum of
increasing cost of medical care and the growing problem of antibiotic resistance, we recom-
mend that physicians rely more on patient interaction and less on antibiotics to achieve patient
satisfaction in the care of patients with respiratory infections." Id.
25. See LAURIE GARRETr, THE COMING PLAGUE, 431 (1994). The author discusses a possi-
ble superbug epidemic. Id. "One of the most disturbing prospects for physicians worldwide
care was the emergence around 1988 of vancomycin-resistant Enterococcus faecium. .. with
Vancomycin the only remaining reliable treatment for staph and strep infections, there was
great concern that resistant enterococci could share their resistant genes with the other, other-
wise untreatable microbes." Id. See also Overprescribing Antibiotics Creating "Superbugs",
USA TODAY (Magazine), Oct 1996, at 4 [hereinafter "Overprescribing Antibiotics. " "Misuse
of broad-spectrum antibiotics and other practices have contributed to increasing resistance
among bacteria, viruses, fungi, and parasites." Id. "Hospitals and physicians are trying to curb
this trend through more strict prescriping of antibiotics and other measures." Id. Many hospi-
tals have responded to concerns about misuse by establishing more stringent prescribing poli-
cies. Id. However, "control of antibiotic use in the outpatient setting is much more difficult."
Id. at 5.
26. Id. "Health experts fear that the rise and spread of antibiotic resistant tuberculosis and
other potentially life-threatening pathogens may push medical technology back 50 years." Id.
"As they attempt to solve this growing problem many are supporting the implementation of
preventative measures... and recommending against overprescribing antibiotics." Id.
27. See infra notes 32-46 - and accompanying text.
28. See infra notes 47-61 - and accompanying text.
29. See infra notes 67-138 - and accompanying text.
30. See infra notes 139-163 - and accompanying text.
31. See Simon Midgley, Old Killers Resisting Arrest: Diseases Last Common in the 19th
Century Have Returned with an Added Danger-the Prospect of an Antibiotic-resistant Super
Bug, TIMES HIGHER EDUCATION SUPPLEMENT, July 19, 1996, at 20. The author notes that many
of the old diseases of the past have returned, as bacteria become increasingly resistant to antibi-
otics. Id. Leading microbiologist disease specialists are taking part in a conference to discuss
how the spread of antibiotic resistance can be contained. Id.
[VOL. 30:4
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antibiotic resistant infections has multiplied at an alarming rate. 32 Once expect-
ed to be eliminated as a public health problem, infectious disease remains a lead-
ing cause of death and disability in the United States and worldwide." Moreover,
what once was thought of as primarily a hospital problem is becoming a problem
in the community as well.' In today's society, with the push toward socialized
medicine and the rapid growth of health care organizations, the problem of antibi-
otic resistance is of great concern.3 In addition, various societal and technologi-
cal changes that have occurred in the last decade facilitate the transmission of
drug-resistant organisms.- Although not the sole factor, overuse or misuse of
32. See LAURIE GARRETr, THE COMING PLAGUE, 431 (1994). The author notes that "unfor-
tunately, we played a trick on the natural world by seizing control of these [natural] chemicals,
making them more perfect in a way that has changed the whole microbial constitution of the
developing countries... we have changed the whole face of the earth by using antibiotics." Id.
See also Overprescribing Antibiotics, supra note 25, at 1. "Antibiotic-resistant pathogens are
emerging at an alarming rate and treatment options are shrinking," warns Terrance 0. Kurtz,
chief epidemiologist at Des Moines General Hospital and associate professor of internal med-
icine at the University of Osteopathic Medicine. Id. The resistance problem is nothing new,
"but it is more of a concern now than in the previous two decades because it is occurring so
rapidly." Id. "How should physicians handle the problem of drug resistance?" Id. The article
notes that physicians must "slow the spread of resistance to antibiotics, especially considering
the speed with which common pathogens are adapting." Id. 'The incidence of penicillin resis-
tance to Streptococcus pneumonia is now 25-35%, just a few years ago, there was no resistance
at all." Id. (quoting Anthony Silvagni, Dean of the University of Health Sciences College of
Osteopathic Medicine).
33. See HORVITZ, supra note 22. The author notes that the threat is hardly limited to this
country, according to a statement issued at the end of 1994 by the World Health Organization
(WHO), antibiotic resistance has reached epidemic proportion in many parts of the globe. Id.
The consequences for impoverished nations, with few medical resources and high rates of
infectious diseases are incalculable. Id. "We do know that people are dying because of resis-
tant infections that once could be treated." Id. (quoting Stuart Levy, author of the antibiotic
paradox).
34. See Steven P. Gelone, Pharm D., Bacterial Resistance: Preparing for the Post-
Antimicrobial Era, PHARMACY TIMES, May 1995, at 31. The author regards the emergence of
resistance in the community environment as occurring mainly because of the selective pressure
of antimicrobial use. Id. at 32. Additionally, as the proportion of families with two working
parents increases, the need for enhanced infection control practices in the day care environ-
ment to decrease the spread of infectious diseases among children may be needed. Id. at 38.
35. Id. "[T]he idea of multiply resistant bacterial infection is no longer a threat; it is a real-
ity of patient care..." Id.
36. See LAURIE GARRETT, THE COMING PLAGUE, 431 (1994). The author comments on the
improper use of antibiotics as "experiments going on all the time in people, creating genuine-
ly pathogenically new organisms." Id. See also Overprescribing Antibiotics, supra note 25, at
5. The author states that "epidemiologists have discovered that growing resistance to poten-
tially life-saving drugs can be attributed to misuse of broad-spectrum antibiotics; increasing
use of prosthetics and invasive diagnostic and therapeutic procedures; growing consumer
demand for antibiotics;.. .routine use of penicillin in cattle and chicken feed; and lax rules gov-
erning the use of antibiotics in other countries." Id.at 2-3. Also, with society becoming more
mobile, increasing international travel, and more children attending day care centers, the prob-
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antibiotics plays a major part in the emergence of the pending epidemic.37
Although antibiotics are deemed harmless, they harness the ability to alter
the future of our nation's health.38 The role of an antibiotic is to gain access with-
in a bacterial cell.39 Once inside, the agent corrupts the processes which keep bac-
teria alive. ' There exist several classes of antibiotics which have unique focal
points of attack against bacteria.4 In general, antibiotics enter our bloodstream to
seek out and destroy bacterial cells. However, the stubborn bacteria have devised
mechanisms of resistance to evade the persistent antibiotics. 2 Once a bacterial
cell mutates to avoid destruction, this mode of resistance is passed on to their
progeny.43 As a result, narrow spectrum antibiotics, which have a limited use to
37. See Gasbarro supra note 11, at 54. Bacteria are becoming increasingly resistant to the
antibiotics used against them which is caused through antibiotic misuse and overuse. Id.
Bacterial strains that are resistant to standard drugs have developed as a result of the con-
tinued misuse of medicines, particularly antibiotics. Id. Antibiotic resistance has spread to a
number of infectious diseases, making it an international concern. Id. See also Overprescribing
Antibiotics, supra note 25, at 4. The author notes that the misuse of broad-spectrum antibiotics
and other practices have contributed to increasing resistance among bacteria. Id.
38. Id.
39. See Gasbarro, supra note 11, at 49.
40. Id. For example, cell-wall synthesis is disrupted by vancomycin, the penicillins, the
cephalosporins, the mono-bactams, bacitracin, and carbapenems. Id. The metabolism of folic
acid that provides bacteria with energy is disrupted by dapsone, isoniazid, trimethoprim, and
the sulfonamides. Id. at 50. Fluoroquinolones interfere with microbial DNA replication and
protein synthesis is inhibited by the macrolides, tetracycline, the aminoglycosides and
mupirocin. Id.
41. See Michelle Meyer, Antibiotics: Are They the Newest Abused Drug, BETrER HOMES
AND GARDENS, Nov. 1996, at 72. The author lists some classes of antibiotics and the types of
infections they are used to treat. Id. Antibiotic common uses: Ampicillin or Amoxicillin-
middle-ear and urinary tract infections, Bactrim-urinary tract infections, Aids-related infec-
tions, diarrheal infections, Biaxin-bronchitis, Legionaires disease, and sexually transmitted
diseases, Ceclor-a general antibiotic used for skin, middle-ear, and upper respiratory infec-
tions, Cipro-urinary tract, bone and joint infections, and traveler's diarrhea due to bacteria,
Keflex-skin, soft-tissue and respiratory infections, Penicillin-strep throats, rheumatic fever,
gonorrhea, and syphilis. Id. (relying on information by Mathew L. Lenz, M.D. , Houston
internist).
42. See Gelone, supra note 34, at 32-39. In general, the author describes the development
of bacterial resistance via four mechanisms: enzymatic destruction or inactivation of the
antimicrobial agent or its metabolite(s), alteration of the target site, decreased drug entry to the
receptor site, and synthesis of an altered metabolic pathway. Id.
43. See Levy, supra note 10 at 103. The author comments on bacterial resistance in stat-
ing:
Bacterial resistance to antibiotics is not a new creation of the past 40 years. It has,
however, become a new clinical problem, because preexistent, naturally occurring
plasmids have become equipped with previously rare resistance genes. The com-
bination of resistance genes on transferable plasmids has enhanced spread of resis-
tance. Bacteria have demonstrated to us a remarkable fluidity in their genetic
material. Under the threat of antibiotics, a small number of them can achieve a
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• 44begin with, are rendered less effective. Therefore, physicians resort to prescrib-
ing the newer, broad spectrum agents to avoid potential resistance.3 With the
over-prescribing of the broad spectrum agents, resistance is soon to follow and
maintaining control of infectious diseases may fall outside the grasp of existing
antibiotics.41
III. WHERE ARE THE "BUGS" IN OUR HEALTH CARE SYSTEM?
In recent years, the inadequate management of infectious diseases has
been a major factor in the dramatic rise of health care costs. 7 The basic frame-
work of our health care system includes patients, providers, and payers. The exist-
ing problem of antibiotic resistance is aggravated by all three entities.4 8 First, a
major problem exists due to patient inconsistencies in seeking treatment and fol-
tenacious survival mode, either by chromosomal mutation, or more frequently, by
acquisition of new genes. These events allow them to persist and grow in the direct
path of what had been efficient killing agents, the antibiotics.
Id.
44. Id. Narrow spectrum agents are limited to specific types of bacteria and have a limit-
ed use, whereas broad spectrum agents kill a wide variety of organisms and are often used by
physicians when the bacteria is unknown. Id. at 44. Penicillin is an example of a narrow spec-
trum antibiotic to which bacteria have developed significant resistance over the years. Id.
Cephalosporins, adaptations of the penicillin structure, are broad spectrum agents useful
against a variety of bacteria. Id.
45. See Anne Novitt-Moreno, Antibiotics: What's Happening to our Miracle Drugs?,
CURRENT HEALTH, Dec. 1995, at 6. The author states that when physicians are faced with a
resistance problem, they can add a second antibiotic that attacks the bacteria in a different way
or they can switch to an entirely different antibiotic. Id. at 7.
46. Id. The author notes that the problem with adding or switching antibiotics is that it
gives bacteria a look at more of our weapons and every time bacteria are exposed to a new
antibiotic, there's always a chance those that are not killed will develop a new kind of resis-
tance. Id. See also Mark Nichols, Outbreak: Doctors Are Struggling to Control Drug Resistant
Bacteria, MACLEAN'S, Sept. 9, 1996, at 42. The author notes that "Doctors dread the day when
events in the microbial world could create a kind of superbug." Id. "Bacteria are sexually
promiscuous, reproduce rapidly and they can swap genes with ease." Id.
47. See McCaig & Hughes, supra note 14 at 217. The study resulted in a finding that the
use of cephalosporins had been increasing. Id. The rationale for the increased use of the new
drugs has been questioned, since they appear to be no more effective for many diseases thanthe
older agents and are more expensive. Id. These changing patterns have implications for
patients, especially children. Id. Such trends can increase health care costs and lead to the
development of antimicrobial resistance. Id.
48. Id. See also Richard Cash, Inappropriate Treatment for Dysentery: Perverse Incentives
and Inadequate Information May Accelerate Antibiotic Resistance, 313 BMJ 181 (1996). The
author states:
If interventions are to modify inappropriate prescribing they "must touch all
groups in the medication cycle (consumer, service provider, supplier, and manufac-
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lowing through with the prescribed therapy. 9 For example, some individuals will
visit the doctor for any sneeze, sniffle, or cough, while others who need medical
attention oftentimes do not receive it.' Likewise, those patients who reap only a
psychological benefit from a visit to a doctor, will leave with an unnecessary pre-
scription."' In addition, lack of patient compliance poses a serious threat. 2
Patients contribute to the problem by discontinuing therapy prematurely, not tak-
important element in reducing the use of inappropriate drugs. Practitioners and drug
sellers focus on the individual, not the group. The opinion and behaviour of the con-
sumer is important in both compliance with treatment and selection of the most
appropriate drug. At a minimum, the public should know what constitutes the best
treatment and that more expensive drugs are not necessarily more effective.
Treatment programmes should be demystified, and the public should be informed
of the benefits and risks of different forms of treatment. Though we are begin-
ning to understand how economics and practice based incentives influence prescrib-
ing practices, we are quite ignorant about how beliefs affect patient compliance. An
interdisciplinary approach involving physicians, economists, behavioural scientists,
communication specialists, manufacturers, and others will need to address the
problem of inappropriate use of antibiotics if we are to avoid the increasingly
alarming reports of worldwide resistance.
Id. at 183.
49. See Overprescribing Antibiotics, supra note 25, at 4. The article comments on patient
behavior in taking antibiotics. Id. "[P]atients who currently view antibiotics as 'cure-alls' must
learn that aches and sniffles associated with common colds and flu do not respond to antibiot-
ic therapy. In addition to demanding drugs, patients are contributing to antibiotic resistance
through noncompliance... more than half of American adults who receive antibiotics fail to
take all of the prescribed doses of the drug." Id.
50. See generally, Gasbarro, supra note 11. The author remarks on patient compliance as
being a factor which contributes to the advent of antibiotic resistance. Id.
51. See Hamm et al., supra note 24 at 56. The results of the study: Sixty-five percent of
the 113 patients with respiratory infection expected antibiotics. Id. Physicians had some abil-
ity to perceive this expectation and frequently prescribed antibiotics for patients who expect-
ed them. Id. Antibiotics were prescribed to over 75% of patients with sinusitis or bronchitis
and to 18% of those diagnosed with only viral infections. Id. See also Arch G. Mainous et al,
Antibiotics and Upper Respiratory Infection: Do Some Folks Think There is a Cure for the
Common Cold?, JOURNAL OF FAMILY PRACrICE, April 1, 1996, at 359. Even though there is no
cure for the common cold, physicians may still prescribe antimicrobial agents, believing that
patients expect to receive them. Id. Although evidence suggests that many patients do not
enter the therapeutic encounter expecting a prescription for antibiotics, physicians may inter-
pret patient behaviors as indicating a desire for antibiotics. Id.
52. See LEVY, supra note 10, at 220. The author states:
An individual should know when, why, and for how long the prescribed antibi-
otic should be taken. He or she should ask these questions of the physician and
then follow the directions for use. If the antibiotic is given to treat a bacterial
infection, it needs to be taken for the entire course of therapy and not simply until
the symptoms disappear. Resistant forms of the causative bacteria can emerge
and increase in number if the drug is stopped before a treatment course is com-
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ing the correct dose, or using leftover medicine from a family member or friend. 3
Due to physician's virtually unrestricted prescribing ability, they repre-
sent the most significant force behind the emergence of antibiotic resistance. -'
Often, physicians rely on information supplied by sales representatives of drug
companies when prescribing antibiotics.5 As a result, the broad spectrum, more
expensive antibiotics are overprescribed.5 6 Other physician contributions to the
problem include choosing an ineffective antibiotic, incorrect doses, the inappro-
priate use in uncomplicated viral diseases, and reliance on antibiotic therapy that
leads to the exclusion of surgical intervention." Moreover, many physicians, in
an effort to maximize their customer base, will succumb to the antibiotic seeking
patient's demands. This result occurs notwithstanding a corresponding diagnosis
which recommends alternative therapy. 9
The payers in our health care system possess the power of the purse, but
have forgone any affirmative action to diminish the unrestrained bugs from infect-
ing society. Although insurance companies have made significant progress in
decreasing health care costs, little has been done in an area of utmost concern-
53. Id. at 209. "If antibiotics are "prescribed-only" drugs, how do individuals gain access
to them? There are many ways, not the least of which is storing and using leftover drugs." Id.
When the author asked people what they do with medicines they do not take, the vast majori-
ty respond that they keep them for later use. Id. "In any number of homes, should you open
the mirrored bathroom cabinets, you'll find bottles of unused drug tablets and liquids." Id.
54. See Gasbarro, supra note 11, at 49. The author remarks on the role the physicians plays
in contributing to the problem of antibiotic resistance. Id.
55. See Cash, supra note 48 at 181. The most up to date information available to health
care providers comes from drug company representatives, whose main aim is to sell their prod-
ucts. Id. Textbooks are uncommon and usually outdated, and peer reviewed journals are rarely
available. Id. Obtaining correct information is not easy. Id. Practitioners who are trying to
increase their income may resort to polypharmacy or prescribe drugs that maximize profits. Id.
56. See LAURIE GARRETT, THE COMING PLAGUE, 431 (1994). The author comments on the
improper use of antibiotics. Id. "It's hard to put the large view into day-to-day medicine.. .you
can't sue a doctor for violating an ecosphere, but you can sue a doctor for failure to give an
antibiotic that you think may have enhanced the possibility of patient survival." Id. (quoting
Mark Lappe, author of Germs That Won't Die). See also Overprescribing Antibiotics, supra
note 25, at 5. "Many physicians who have been in practice a long time have bad habits.. .We
all get used to using certain antibiotics.. .If an antibiotic does the job for us, we use it, even if
a more specific antibiotic is available." Id. (quoting Terrance 0. Kurtz, Chief Epidemiologist
at Des Moines General Hospital).
57. See Gasbarro, supra note II at 51 (Table 1). Table I lists the ways in which a physi-
cian or patient may contribute to bacteria's ability to develop resistance. Id.
58. See Cash, supra note, at 181. The author notes that physicians have suggested that
they are only trying to maintain their customer base by responding to customer demands when
they overprescribe or use the latest, most expensive drugs. Id.
59. See Hamm et al., supra note 24, at 56. The author says that a physician may feel a
duty to treat the patient presenting with a mild but uncomfortable illness with antibiotics, even
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antibiotic resistance.6 Due to the inadequate control of the pending epidemic by
medical remedies, the remainder of this article focuses on why legal regulations
are needed to hinder the advancing army of resistant bacteria. 6,
IV. WHY WE NEED TO REGULATE ANTIBIOTIC PRESCRIPTIONS
Recent studies indicate that the infectious disease mortality rate has risen
nearly sixty percent, becoming the third leading killer of Americans.62
Furthermore, the Center for Disease Control (CDC) estimates that more than half
of the infection related deaths involve resistant bacteria.63 Although physicians
60. See LEVY, supra note 10, at 238. The author comments on the cost to society and the
individual of antibiotic resistance, by stating :
Certainly the most critical consequence of antibiotic resistance is the compromised
therapy of human disease. Another mounting and disturbing consequence of
resistance, however, revolves around the price tag for treatment. Someone must pay
for the higher costs of newer drugs that are needed to combat resistant bacteria.
Medical insurance companies, the government, and the individual now face, and
will continue to face, higher and higher prices for the new antibiotics being
developed to treat the multiresistant forms of bacterial disease.
Id.
61. See Mainous et al., supra note 51, at 359. The seemingly benign act of prescribing
an antibiotic such as amoxicillin for a cold does little or no physical harm to the patient and
keeps the practice economically viable. Id. This particular perspective may be based on prac-
ticemanagement behaviors deemed effective in a fee-for-service model of health care delivery.
Id. In closed-panel managed care organizations, the ability of the patient to change physicians
may be greatly impeded, thereby decreasing the perceived economic threat of patients leaving
the practice if they do not receive antibiotics for colds. Id. The author also adds:
Even guidelines to be voluntarily followed have shown positive effects in increas-
ing the appropriate use of antibiotics. Although most of the guidelines have been
proposed for small closed systems such as hospitals, they may be useful to man-
aged care organizations. However, open systems, such as the general community of
physicians, could also be influenced by a clinical guideline for treating the com-
mon cold. Evidence suggests that clinical guidelines for medical practice can be
particularly effective when presented in the context of a specific educational inter-
vention but seldom change practice when disseminated through publication in
journals or unsolicited mailed material.
Id.
62. See Pinner et al., supra note 19 , at 189. The authors conclude that between 1980 and
1992, the death rate due to infectious diseases as the underlying cause increased 58 percent. Id.
"Despite historical predictions that infectious diseases would wane in the U.S., recent data sug-
gests that infectious disease mortality rate has been increasing steadily." Id.
63. See Horvitz, supra note 22, at 38. "Exact statistics are hard to come by.. .what we
don't know is whether they died of a heart attack and also had an infection or died of the infec-
tion itself... we do know that people are dying because of resistant infections that once could
be treated." Id. (quoting Stuart Levy, author of THE ANTIBIOTIC PARADOX).
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and patients cannot be deemed fully responsible, the misuse and overuse of antibi-
otics poses a significant threat to the existing arsenal of antimicrobials."
Since major drug manufacturers have abandoned the replenishment of the
antibiotic arsenal until recently, the hypothetical epidemic becomes a reality with
no assistance from reinforcement troops.' For example, no new antibiotics have
been developed for the last two years.' Since it takes fourteen years of research
and approximately 400 million dollars for a drug to reach the market, the resis-
tance problem appears to be far from under control." Therefore, in order to remain
one step ahead of the bacteria, the only plausible remedy is to construct and
enforce legal regulations."
In the 1970's, regulatory agencies played a major part in preserving the
health and safety of our nation.' Once again, as the health of our nation is put in
jeopardy, it is time to bring forth our public representatives to devise a regulato-
ry remedy. A physician can be likened to a nuclear power plant to allow regulato-
64. See Overprescribing Antibiotics, supra note 25, at 4. The article notes that growing
resistance to potentially life-saving drugs can be attributed to misuse of broad-spectrum antibi-
otics. Id. Although, health experts agree that any use of antibiotics can potentially lead to
resistance, the misuse and overuse of antibiotics has contributed greatly to the growing prob-
lem. Id.
65. See Horvitz, supra note 22, at 38. "Many drug manufacturers have abandoned the
development of antibiotics almost entirely... the reason, not surprisingly, is economics...
drug companies have concentrated on cardiovascular and abandoned infectious diseases ....
Patients given cardiovascular medication such as beta blockers will take the medicine for the
rest of their lives while people with infections will only need a drug for the duration of their
illness, usually no longer than a week or two." Id. (quoting Stuart Levy, author of THE
ANTimIoric PARADOX).
66. Id. Levy underscores a more important problem: "There have been no new drugs for
the last 2 years... all the ones that have been done in the nineties are modifications of exist-
ing drugs-so whatever resistance developed in the old ones is carrying over to the new ones."
Id.
67. See Novitt-Moreno, supra note 45, at 6. The author asks: "How do we stop the super-
bugs?" Id. "Do we just keep on inventing new antibiotic weapons?" Id. "We could, but there's
a catch: It takes about 14 years of research and almost 400 million dollars to develop every
new antibiotic .... And after all that work and money, some dangerous bacteria could find a
way to resist it almost overnight... Scientists believe that instead of making new antibiotic
weapons, we should be more careful using the ones we already have." Id.
68. See Gasbarro, supra note 11, at 49. The author concludes that antibiotics are still
extremely effective managers of bacterial infection, and the risks posed by resistance can be
greatly diminished through use of judicious medication use. Id.
69. See ROGER W. FINDLEY & DANIEL A. FARBER, Environmental Law in a Nutshell, 23 (3d
ed. 1992). The authors comment on the importance of NEPA in stating: "prior to the passage
of NEPA, some agencies contended they lacked the statutory authority to consider environ-
mental issues ... For example, the Nuclear Regulatory Council (NRC) contended that the ther-
mal pollution caused by nuclear power plants was beyond their jurisdiction ... One important
result of NEPA is to ensure every agency has the authority to consider the environmental con-
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ry action to prevent a potential disaster.7°This analogy is not farfetched. In each
case, the physician and power plant are granted a license which allocates permis-
sion to the holder to conduct activities within the confines of the license.'
However, if the privilege is abused to the point of jeopardizing the health and
safety of society, the license can be revoked or suspended.72 Just as the nuclear
power plant is subject to health and safety guidelines, a physician should meet
guidelines when prescribing antibiotics. Although physicians are subject to tort
liability restraints," they possess "the power of the pen" and are virtually unre-
stricted when it comes to prescribing antibiotics. 4 The physician has been con-
fined in other areas of medicine with prescribing limitations. 7 These limitations
70. See Northern States Power Co. v. Minnesota, 447 F.2d 1143 (8th Cir. 1971), aff'd 405
U.S. 1035 (1972). The court concluded :
Thus, through direction of the licensing scheme for nuclear reactors,
Congress vested the AEC with the authority to resolve the proper balance
between desired industrial progress and adequate health and safety standards.
Only through the application and enforcement of uniform standards promulgat-
ed by a national agency will these dual objectives be assured.
Id.
71. See Atomic Energy Act of 1954, 42 U.S.C.A. § 2011-2282. See also FINDLEY &
FARBER, supra note 69 at 191. The authors note that the primary purpose of regulation is to pro-
tect human life and the environment from excessive exposure to radiation. Id. The Nuclear
Regulatory Commission (NRC) exercises broad regulatory and licensing authority over essen-
tially all activities related to civilian nuclear materials. Id.
72. See Pacific Gas & Electric Co. v. State Energy Resources Conservation & Development
Comm'n, 461 U.S. 190 (1983) (holding that the construction of nuclear power plants was con-
ditioned on a determination by a state agency that adequate storage facilities and means of dis-
posal were available for nuclear waste and approved by NRC).
73. Examples of tort liability include, but are not limited to, medical malpractice claims
where the practitioner has not met the standard of care in the treatment of a certain disease state
or condition.
74. There are currently no limitations placed on the ability of a physician to prescribe
antibiotics. See generally OHIO REVISED CODE. been confined in other areas of medicine with
prescribing limitations."
75. Among the various restrictions imposed on practitioners are the following:
21 C.F.R. § 1306.04 (1996) which states:
(a) A prescription for a controlled substance to be effective must be issued for a
legitimate medical purpose by an individual practitioner acting in the usual
course of his professional practice.
OHIO REV CODE ANN. § 4731-11-05 which states:
(A) A physician shall not utilize anabolic steroids, growth hormones, testosterone
or its analogs, human chorionic gonadotropin (HCG), or other hormones for
the purpose of enhancing athletic ability.
(B) A physician shall complete and maintain patient medical records which
[VOL. 30:4
14
Akron Law Review, Vol. 30 [1997], Iss. 4, Art. 5
http://ideaexchange.uakron.edu/akronlawreview/vol30/iss4/5
INFECTIOUS DISEASES
mainly encompass areas which may present a danger to society if permitted to run
accurately reflect the utilization of any substance or drug described in this
rule. Patient medical records shall indicate the diagnosis and purpose for which
the substance or drug is utilized, and any additional information upon which the
diagnosis is based.
(C) A violation of any provision of this rule, as determined by the board, shall
constitute failure to use reasonable care discrimination in the administration
of drugs, as that clause is used in division (B) (2) of section 4731.22 of the
Revised Code; and "a departure from, or failure to conform to, minimal stan-
dards of care of similar practitioners under the same or similar circumstances,
whether or not actual injury to the patient is established," as that clause is
used in division (B) (6) of section 4731.22 of the Revised Code.
OHIO REV CODE ANN. § 4731-11-04 (Banks-Baldwin 1996) which states:
(A) A physician shall not utilize a schedule Il or IV controlled substance for pur-
pose of weight reduction unless it has an FDA approved indication for this pur-
pose and then only in accordance with all of the provisions of this rule.
(B) A physician may utilize a schedule I or IV controlled substance for the pur-
poses of weight reduction in the treatment of obesity only as an adjunct, in accor-
dance with the FDA approved labeling for the product, in a regimen of weight
reduction based on caloric restriction, provided that all of the following condi-
tions are met:
(1) Before initiating treatment utilizing a schedule III or IV controlled substance,
the physician determines through review of his own records of prior treatment, or
through review of the records of prior treatment which another treating physician or
weight-loss program has provided to the physician, that the patient has made a
substantial good-faith effort to lose weight in a treatment program utilizing a reg-
imen of weight reduction based on caloric restriction, nutritional counseling,
behavior modification, and exercise, without the utilization of controlled sub-
stances, and that said treatment has been ineffective...
(2) The physician shall not initiate or shall discontinue utili zing all schedule 1II
or IV controlled substances immediately upon ascertaining or having reason to
believe:
(a) That the patient has failed to lose weight while under treatment with a con-
trolled substance or controlled substances over a period of fourteen days, which
determination shall be made by weighing the patient at least every four-
teenth day, except that a patient who has never before received treatment for obe-
sity utilizing any controlled substance who fails to lose weight during his first
such treatment attempt may be treated with a different controled substance for an
additional 14 days...
(C) A violation of any provision of this rule, as determined by the board, shall con-
stitute failure to use reasonable care discrimination in the administration of drugs,
as that clause is used in division (B) (2) of section 4731.22 of the Revised Code; and
"a departure from, or failure to conform to, minimal standards of care of similar prac-
titioners under the same or similar circumstances, whether or not actual injury to the
patient is established," as that clause is used in division (B) (6) of section 4731.22
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afoul of certain therapeutic recommendations.76 A physician who violates the
prescribing restrictions may have their license suspended or revoked.
77
Some physicians and other experts in the medical field agree that guide-
lines and regulations need to be imposed on antibiotic prescribing before the res-
tance problem becomes uncontrollable. 8 One way that doctors can aid the battle
76. See generally, OHIO REV CODE ANN. Drug Laws of Ohio (Banks-Baldwin 1996). The
restrictions which exist on a physicians prescribing ability deal with controlled substances,
drugs entities having a high potential for abuse whether it is physical, psychological or both.
Id. This is done to ensure the health and safety of individuals in the administration of health
care. In the antibiotic arena, patients and physicians have become addicted to the healing
power, envisioning antibiotics as "cure-alls." Therefore, due to the psychological abuse
potential of antibiotics, they should be dealt with in a similar manner to controlled substances.
77. See OHIO REV CODE ANN. § 4731.22 (Banks-Baldwin 1996) which states in part that:
The state medical board, pursuant to an adjudicatory hearing under Chapter 119 of
the Revised Code and by vote of not fewer than six of its members, shall, to the extent
permitted by law, limit, revoke, or suspend a certificate, refuse to register or refuse
to reinstate an applicant, or reprimand or place on probation the holder of a cer-
tificate for.... Failure to use reasonable care discrimination in the administration
of drugs, or failure to employ acceptable scientific methods in the selection of
drugs or other modalities for the treatment of disease.
OHIO REv CODE ANN. § 4731.22 (A) (2) (Banks-Baldwin 1996). License suspensions and
revocations are well documented under Ohio case law. See, e.g., Gingo v. State Medical
Board, 564 N.E.2d 1096 (Ohio App. 1989). The court held that "Dr. Gingo's weight loss 'sys-
tem' is precisely the opposite of what one would expect to find in a program purported to
enhance overall good health. In truth, his proposed solution to an admittedly significant prob-
lem -obesity -ultimately promotes a far more alarming epidemic: drug misuse ..... Id. at 1099;
Arlen v. State, 399 N.E.2d 1251 (Ohio 1980) (stating that "the purpose of the General
Assembly in providing for administrative hearings in particular fields was to facilitate such
matters by placing the decision ... with boards... equipped with the necessary knowledge and
experience pertaining to a particular field.") (quoting Farrand v. State Medical Board, 151
Ohio St. 222, 224 (1949)) Id. at 1254. In Arlen, the court held that the physician's licens should
be suspended for improperly dispensing drugs. Id.; Sickling v. State Medical Bd., 575 N.E.2d
881, 883 (Ohio App. 1991) (holding that physician's license be revoked for violating R.C.
4731.22 (B), which states in part: "Failure to use reasonable care discrimination in the admin-
istration of drugs, or failure to employ acceptable scientific methods in the selection of
drugs.. .in the treatment of disease..."); Stegall v. Ohio State Medical Bd., 635 N.E.2d 1291
(Ohio App. 1993) (holding that the board's adoption of weight control rule was properly based
on medical testimony and board's own expertise) The court added "there can be no question
that the board has the ability to adopt rules setting specific minimum standards of care by
adopting administrative regulations." Id. at 1294; Roy v. Ohio State Med. Bd., 655 N.E.2d 771
(Ohio App. 1995) (affirming the authority of State Medical Board to revoke physician's license
to practice includes the authority to revoke it permanently); But see In re Williams, 573 N.E.2d
638 (Ohio 1991) (affirming Court of Appeals reversal of determination by State Medical Board
that physician had failed to conform to minimal standards of medical practice by prescribing
controlled substances as part of a weight control treatment regimen).
78. See Overprescribing Antibiotics, supra note 25, at 4. The article notes that many hos-
pitals have responded to concerns about misuse by establishing more stringent prescribing
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against bacteria is to utilize judicious management in prescribing drugs.'
However, when the physician in a community setting depends on a strong cus-
tomer base for their livelihood, the physician seems left without an alternative
when confronted with an antibiotic seeking patient."0 A regulatory scheme will
promote uniformity and enable physicians to "just say no."8' Another advantage
to a regulatory program is the prevention of doctor shopping. 2 If a patient leaves
a doctor's office empty-handed, they will be less likely to seek another provider
if they will be met with similar results.83 The regulations would also serve as an
educational tool to enlighten physician and patient understanding of the extent of
a potential disaster." As a result, when faced with legal regulations, physicians
will be less likely to prescribe sight unseen or cause unknown.8 Furthermore,
patients will be less likely to expect antibiotics and will be unable to "go around
the corner" to receive them.
policies. Id. In some institutions, broad-spectrum antibiotics can be prescribed only by infec-
tious disease specialists. Id. "By restricting the use of some antibiotics, we can stem the tide
of resistance until new antibiotics hit the market." Id. (quoting Anthony F. Ognjan, Chief of
Infectious Diseases, Mount Clemens (Mich.) General Hospital).
79. See Cash, supra note 48 at 181. The author states that physicians have suggested that
they are only trying to maintain patient satisfaction by responding to customer demands when
they overprescribe or use the latest, most expensive drugs. Id.
80. Id. Practitioners who are trying to maximize profits may resort to polypharmacy or
prescribe drugs that increase their income. Id. The author asks: "What can be done about this
behavior?" Id. The author responds: "Educational programs are necessary, but how the infor-
mation is presented and reinforced is critical." Id. In an attempt to change prescribing patterns
for treating diarrhea in a government hospital in Mexico, two techniques were used: (1) they
involved the physicians in developing a treatment algorithm and, (2) they performed and pub-
licized periodic audits of each physician. Id. The use of antibiotics dropped from 80% to 30%
of all cases of diarrhea seen in the clinic. Id. Moreover, these changes were sustained 18
months after starting the program. Id.
81. See Horvitz, supra note 22, at 39. "A lot of people say, ' if my physician doesn't give
a drug to me, I'll get it from somewhere else."' Id. (quoting Amy Magen, a spokeswoman for
Eli Lilly Drug Company). The author adds: "This is one time when just saying no to drugs
may accomplish its objective." Id.
82. The regulatory proposal is set forth in Section IV(B) , infra. See also LEVY, supra
note 10 at 212. The author states: "We are at a point in medical history where people expect
a pill for every ill." Id. "Whom do we blame, the physician or the patient, when an antibiot-
ic is obtained for the common cold?" Id. The author notes: "People welcome the report from
the local mechanic that all their car needed was an adjustment, a new spark plug, but not a total
motor overhaul.. .we do not argue about paying for his time and expense.... Why then should
patients be disappointed when the doctor says that their viral disease needs only aspirin, flu-
ids, and rest?" Id. at 213.
83. Id. at 221.
84. Id. The author notes that "by using these drugs effectively, each one of us protects the
world population from the continued emergence and spread of resistance determinants.., we
must take responsibility for using antibiotics properly, since this will protect the future health
of ourselves, our families, and our whole society." Id. at 221.
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Legal restrictions on antibiotic use will also provide third party payers
with the necessary ammunition to mount an attack of their own. The majority of
prescriptions in the U.S. are paid by third party prescription insurance plans.8
The regulations will enable the insurance company to allow monetary incentives
for those patients and physicians complying with the regulations." Most pre-
scription payers already have the necessary equipment to enforce an additional
restriction. The insurance companies have a drug utilization review (DUR) pro-
gram which recognizes and corrects other therapeutic inadequacies.89 The DUR
program has been successful at enhancing therapeutic outcomes and diminishing
86. See LEVY, supra note 10 at 221. The majority of Americans are able to have reduced
costs of prescriptions through some type of prescription insurance plan. Id. "Someone must
pay for the higher costs of newer drugs that are needed to combat resistant bacteria." Id. at 238.
"Medical insurance companies, the government, and the individual now face higher and high-
er prices for the new antibiotics being developed to treat the multiresistant forms of bacterial
disease." Id. See also Cash, supra note 48. Inappropriate drugs cost more because adequate
treatment can be achieved with fewer and less expensive drugs. Id. at 181. Also, in describing
methods incorporated in a managed care setting, the author notes that such methods might be
effective for physicians working as employees in hospitals or health maintenance organiza-
tions, where standards of case management can be maintained. Id.
87. Id. "If interventions are to modify inappropriate prescribing they must touch all the
groups in the medication cycle." Id. The author notes that a better informed consumer is an
important element in reducing the inappropriate use of antibiotics, Id. See also KLAIS HEALTH
NETWORK PROVIDER DIRECrORY, Akron, Ohio (1997). The directory notes that "your decision
whether or not to use a Klais Health Network provider may affect the level of the benefits you
receive.. .you are free to choose a provider which is not part of the Klais Health Network, but
you will generally receive lower out of pocket charges when utilizing a Klais Health Network
provider...because our providers have agreed to supply health care services at pre-negotiated
discounts." Id.
88. Telephone Interview with Michael Dennis, Registered Pharmacist in Canton, Ohio
(Jan. 15, 1997). In addressing the third parties relationship to prescription filling, Mr. Dennis
states:
The third party insurance companies have a great deal to do with drug therapy. I am
constantly calling them for an override code or approval for one thing or another.
For example, if a patient is attempting to get an early refill on a medication, the
insurance company will want to know the reason before payment is granted. I will
phone the doctor to check the dosing on the medication and relay this infor-
mation to the insurance carrier to get an override.
Id.
89. Id. Mr. Dennis further remarks on the successes of the DUR program:
The DUR program combines a vast array of therapeutic information into a com-
puter program to screen inappropriate or potentially dangerous interactions. The
program has been a great tool in the practice of pharmacy. Although pharmacies
have a DUR program as well, the third party carrier adds an extra dimension. They
serve as a centralized database for ensuring optimal drug therapy for the patient.
Where a cash customer may get past the pharmacy in some instances, when a third
party is paying for the medication, it is amazing what information gets revealed.
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health care costs by instituting a checks and balances system in the drug therapy
arena.90 In Ohio, the Ohio Administrative Code established a DUR board to
review drug utilization in claims submitted to the Department of Health and
Human Services.9 ' Although the initiative is a step in the right direction, a
closer look reveals the program is largely voluntary. 9 The Ohio
90. Id. Mr. Dennis, in discussing the checks and balance system notes: "The insurance
company is able to cross-reference all prescriptions they receive for payment." Id. The phar-
macist interviewed spoke on the effects of third party insurance companies on the advent of
antibiotic resistance: "Within the last year, I have begun to see more drug screening in the
antibiotic field." Id. "For example, if a patient was taking an antibiotic for more than the rec-
ommended number of days for optimal treatment, the company will refuse to pay for the med-
icine until the pharmacist has spoken with the physician to get an explanation." Id. "The insur-
ance company will also refuse to pay for claims which contain a drug-drug or drug-disease
state interaction." Id. "This process is time-consuming, yet beneficial to provide optimal drug
therapy." Id.
91. A DUR (drug utilization review) program is set forth in OHIO ADMINISTRATIVE CODE §
5101:3-9-16 (Banks-Baldwin 1996) providing for the ongping review of claims submitted to
the Department of Health and Human Services. OHIO ADMINISTRATIVE CODE § 5101:3-9-16
states:
(A) Membership
(1) The DUR board shall include health care professionals appointed by the
director of human services, who have recognized knowledge and expertise in
one or more of the following:
(a) The clinically appropriate prescribing of covered outpatient drugs;
(b) The clinically appropriate dispensing and monitoring of outpatient
drugs;
(c) Drug use review, evaluation, and intervention;
(d) Medical quality assurance.
(2) The DUR board shall be comprised of four licensed and actively prac-
ticing physicians, at least one of which is a doctor of osteopathic medicine,
four licensed and actively practicing pharmacists, and one nonvoting
department staff person...
(C) Duties.
(1) The DUR board shall review and recommend multiple levels of interven-
tion for physicians and pharmacists targeted toward therapy problems or
individuals identified in the course of retrospective drug use reviews.
Intervention programs shall include, in appropriate instances at least:
Written, oral, or electronic reminders containing patient specific and/or drug
specific information and suggested changes in prescribing or dispensing prac-
ices, communicated in a way to ensure the privacy of patient related infor-
mation....
92. Id. The unfavorable result referred to is the lack of enforcement power contained with-
in the DUR board establishment. Id. The DUR board may deter certain provider conduct, but
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Administrative Code Section 5101-3-9-16 "recommends" interventions and
"reminds" the physicians and pharmacist of more appropriate therapy. 3 This may
serve as an educational tool to some practitioner's way of thinking, but a more
stringent approach is needed to control their method of prescribing.' The
proposed antibiotic regulations will enable the third party payer to facilitate the
process of health care management with the imposition of monetary controls on
drug use.9 In the absence of such a consumer based remedy, antibiotic use will
continue to thrive because someone else is footing the bill.9
93. Id.
94. Telephone interview with Robert Madrigal, Registered Pharmacist in Barberton, Ohio
(Feb. 10, 1997). Mr. Madrigal comments on the current DUR program:
Currently, the DUR program in Ohio may make things more difficult to fill a pre-
scription, but overriding the intervention is not very difficult at all. Although, I pay
attention to the recommendations, many other pharmacist, nurses, and physicians
may just override the message without a second thought. However, if a situation were
to arise where a diminution in payment is seen, such as where a pmgrnam mandates
generic substitution, a closer look seems to be in order. When money is involved, it
may make people stop and think.
Id.
95. Id. The pharmacist interviewed spoke on the effects of third party insurance compa-
nies on the advent of antibiotic resistance: "Within the last year, I have begun to see more drug
screening in the antibiotic field." Id. "For example, if a patient was taking an antibiotic for
more than the recommended number of days for optimal treatment, the company will refuse to
pay for the medicine until the pharmacist has spoken with the physician to get an explanation."
Id. "The insurance company will also refuse to pay for claims which contain a drug-drug or
drug-disease state interaction." Id. "This process is time-consuming, yet beneficial to provide
optimal drug therapy." Id.
96. Telephone interview with Phillip Michael, Registered Pharmacist in Charleston, West
Virginia (Jan. 10, 1997). Mr. Michael regards the antibiotic resistance problem as an epidem-
ic already. He comments on the prescribing habits of physicians:
The classic scenario exists where a patient with prescription insurance comes into
the pharmacy holding a prescription for the newest and most expensive antibi-
otic on the market. He or she will leave paying under ten dollars as a copay-
ment for a drug which may cost the insurance company well over 100 dollars.
After speaking with the patient, I conclude that they probably have a touch of the
flu, to which antibiotics are of no avail. A second patient arrives almost simultaneously
with a prescription from the same physician. However, in this case the patient does not
carry prescription insurance. The prescription is written for an inexpensive narrow
spectrum antibiotic. This patient, I also believe had a touch of the flu.
Id. The interviewee acknowledged that prescribing habits of physicians seemed to correspond
directly with who was footing the bill. The following regulatory proposal would hinder this
inappropriate prescribing cycle. Id.
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V. THE POWER TO REGULATE ANTIBIOTIC PRESCRIPTIONS
The power to regulate antibiotic prescribing can be obtained from two
existing regulatory schemes.97 First, under the Ohio Public Health Laws, a broad
authority exists to maintain public health and safety." For example, in 1996, the
Ohio legislature established a resolution which would impose monetary sanctions
on health care practitioners for violating therapeutic treatment guidelines in cer-
tain areas." Although antibiotic prescribing restrictions are not specifically enter-
tained by the resolution, the power to confine treatment methods in highly volatile
97. See infra notes 98-100 and accompanying text for a discussion on Public Health Laws
of Ohio. See also infra notes 101-104 and accompanying text for a discussion of the Drug
Laws of Ohio.
98. See Omo REV CODE ANN. § 3709.22 (Banks-Baldwin 1996) which states:
Each board of health of a city or general health district shall study and record the
prevalence of disease within its district and provide for the prompt diagnosis and con-
trol of communicable diseases. The board may also provide for the medical and
dental supervision of school children, for the free treatment of cases of venereal
diseases, for the inspection of schools, public institutions, jails, workhouses, chil-
dren's homes, infirmaries, and county homes, and other charitable, benevolent,
and correctional institutions.
id. See also OHIO REV CODE ANN. § 3707.04 (Banks-Baldwin 1996) which states:
In time of epidemic or threatened epidemic, or when a dangerous communicable
disease is unusually prevalent, the board of health of a city or general health dis-
trict, after a personal investigation by its members or executive officer to
establish the facts in the case, and not otherwise, may impose a quarantine on
vessels, railroads, or other public or private vehicles conveying persons, baggage,
or freight, or used for such purpose. The board may make and enforce such rules
and regulations as are wise and necessary for protection of the health of the people
of the community....
Id.
99. See OHIo REV CODE ANN. § 3702.11 (Banks-Baldwin 1996) which states:
The director of health shall adopt rules establishing safety standards, quality of care
standards, and quality of care data reporting requirements for each of the follow-
ing:
(A) Solid organ and bone marrow transplantation;
(B) Stem cell harvesting and reinfusion;
(C) Cardiac Catheterization;
(D) Open-heart surgery;
(E) Obstetric and newborn care;
(F) Pediatric intensive care;
(G) Operation of linear accelerators;
(H) Operation of cobalt radiation therapy units;
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public health areas is already in place."°
Secondly, a more specific power to control prescribing habits is contained
in the Drug Laws of Ohio.101 For example, under 4731.22 of the Ohio Revised
Code, the state medical board may revoke or suspend a physician's license for
"failure to use reasonable care discrimination in the administration of drugs, or
failure to employ acceptable scientific methods in the selection of drugs or other
modalities for the treatment of disease." Prescribing antibiotics on demand with-
out utilizing proper diagnosis and therapeutic recommendations arguably falls
within the realm of this statute.' °0 Although antibiotics have yet to be included in
100. The Ohio Revised Code grants investigative powers to seek out public health prob-
lems, see OHIO REV CODE ANN. § 3702.19 which states in part:
In investigating possible violations of § 3702.14 of the Revised Code, or in con-
ducting hearings under § 3702.20 of the Revised Code, the director of health
may administer oaths, order the taking of depositions, and issue subpoenas
compelling attendance of witnesses or production of documents.
Id. The Ohio Revised Code contains a provision to monitor compliance with public health pro-
grams, see OHIO REV CODE ANN. § 3702.15 (Banks-Baldwin 1996) which states:
The director of health shall monitor health care providers for compliance with
the safety and quality of care standards established in the rules adopted under §
3702.11 of the Revised Code. The director may inspect any health care provider
as the director determines adequate to monitor compliance. The rules may
require health care providers regularly to issue reports and undergo indepen-
dent audits.
Id. Finally, an enforcement provision under the Public Health Laws of Ohio can be seen in the
OHIo REV CODE ANN. § 3702.20 (Banks-Baldwin 1996) which states in part:
If the director of health determines that a person has violated § 3702.14 of the
Revised Code, the director, after affording the person an opportunity for a hearing
conducted in accordance with Chapter 119 of the Revised Code, shall impose a civil
penalty of not less than one thousand dollars and not more than two hundredfifty
thousand dollars on the person. In addition to the civil penalty, for a second or sub-
sequent violation of § 3702.14 of the Revised Code, or for a first violation
that the director determines has caused or poses an imminent threat of serious
physical or life-threatening danger, the directorafter affording the person an
opportunity for a hearing in accordance with Chapter 119 of the Revised Code, may
issue an order that the person cease operating the health service.
Id.
101. See OHIO REV CODE ANN. § 4722.31 (Banks-Baldwin 1996).
102. OHIO REV CODE ANN. § 4722.3 1(B) (Banks-Baldwin 1996) grants the state medical
board authority, pursuant to adjudicatory hearings, to limit, revoke, or suspend a physician's
license for : "Failure to use reasonable care discrimination in the administration of drugs, or
the failure to employ acceptable scientific methods in the selection of drugs or other modali-
ties for the treatment of disease." OHIO REV CODE ANN § 4731.22 (B) (2). Furthermore,
administrative action may be taken for "selling, prescribing, giving away, or administering
drugs for other than legal and legitimate therapeutics." Id. at Sec. B (3).
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this regulatory arena, the imposition of medically proven and scientifically reli-
able antibiotic guidelines will add bite to the existing bark which underlies efforts
to control the pending epidemic.' 3 As a result, under a general police power or
under more specific prescribing limitations, antibiotic use guidelines are an
appropriate extension of existing legislation.'"
VI. THE REGULATORY PROPOSAL
Thus far, this article has discussed the nature of the antibiotic resistance
problem, the causative agents, why there is a great need for legal regulations, and
where the power to regulate antibiotic can be obtained. The following regulato-
ry proposal is geared toward alleviating the strain of resistant organisms with-
out compromising the quality of health care. Other regulations have been suc-
cessfully administered in the hospital and managed care settings.' - However, a
broad spectrum attack at the community level is necessary to facilitate uniformi-
ty and control."~ Congress and the states should adopt regulations from the fol-
lowing proposals.
103. See Mainous et al., supra note 51 (concluding that "a majority of persons receiving
medical care... are given prescriptions for an unnecessary antibiotic. Unchecked, this practice
may lead to greater antibiotic resistance and unnecessary use of health care resources. Future
research should focus on the ability to institute behavioral changes....").
104. Id. The behavioral changes Dr. Mainous speaks of can be obtained with the use of a
comprehensive regulatory strategy that will provide educational and enforcement provisions to
aid in the battle against the bacterial world. Id.
105. See Controlling the Costs of Antibiotic Resistance, 15 Clin. Ther. 3 (1993). The
author states:
Excessive and inappropriate use of antibiotics in hospitals contributes to the
development of antibiotic resistance. Denver's three major teaching hospitals
have developed a multifaceted approach that has curbed inappropriate antibi-
otic prescribing. A joint antibiotic-use committee with representatives from
each hospital's pharmacy and therapeutics committee developed a single
antibiotic formulary for systemically active bacterial agents, based on sim-
plicity, clinical efficacy, previous use patterns, local resistance patterns, and rel-
ative cost. This formulary includes primary agents, ordered at the prescriber's dis-
cretion; secondary agents, ordered only for an approved condition; and restrict-
ed agents which have been used excessively or inappropriately in the past, and
are now dispensed only after consultation with an infectious disease specialist.
Id.
106. See Cash, supra note 48 at 181. The author notes that keeping abreast of changing pat-
terns of microbial resistance presents a formidable challenge to all those prescribing antibi-
otics. Id. The author adds that when national standards are developed for treating infectious
diseases, recommendations must be transmitted to local practitioners and drug sellers. Id. See
also Mainous et al., supra note 51.The author remarks that guidelines on the proper use of
antibiotics have proven to be valuable in the hospitals and managed care settings. Id. He also
states, "open systems, such as the general community of physicians, could also be influenced
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First, physicians should be prohibited-with certain exceptions-from
prescribing antibiotics without physically observing the patient.'7 Such excep-
tions might include antibiotics prescribed as a preventive measure for persons
traveling to areas where an outbreak of a particular disease has occurred," or in
instances where the antibiotic is being prescribed as a preoperative treatment.' °9
Other exceptions might be allowed where the physician prescribes an antibiotic to
contain the spread of an infection in a closed environment."t0 Under circum-
stances where physical observation is impossible or impractical,"' a physician
may initiate antibiotic therapy with a narrow spectrum agent if the physician cer-
tifies the need for antibiotic treatment.12
A certification procedure should also be established to document the need
for a particular antibiotic prescription. This would require the physician to com-
plete a standard form indicating the diagnosis and why the physician believes an
antibiotic is warranted under the circumstances.
Narrow spectrum antibiotics should be regulated so that they are only pre-
be particularly effective when presented in the context of specific educational intervention."
Id.
107. See Overprescribing Antibiotics, supra note 25, at 4. The author notes that control of
antibiotic use in the outpatient setting is difficult, Id. "Many physicians who have been in
practice a long time have bad habits.... [W]e all get used to using certain antibiotics ... even
if a more specific one is available." Id. (quoting Terrance 0. Kurtz, Chief Epidemiologist at
Des Moines General Hospital). Kurtz also suggests that physicians refrain from prescribing
by phone, favoring an office visit and appropriate tests to confirm a diagnosis before dispens-
ing medication. Id.
108. Cf. Meyer, supra note 41 at 73. "Don't take antibiotics to prevent a disorder such as
traveler's diarrhea, you only increase your risk of picking up a resistant infection." Id. (quot-
ing Stuart Levy, author of THE ANTIBIOTIC PARADOX).
109. See LEVY, supra note 10, at 115. The author states that antibiotics are recommend-
ed for disease prophylaxis, that is to prevent infection at times when there is a known risk of
contracting an infectious illness. Id. The author adds that medical practitioners and surgeons
know that antibiotics can be extremely useful in preventing postsurgical infections. Id. at 128.
The author states, "For this use, the effectiveness of the antibiotic as a prophylactic agent is,
almost by definition, limited to the short period of time before, during, and sometimes imme-
diately after surgery.... A physician need not prescribe additional drugs beyond this protective
period unless there is clear evidence of infection." Id.
110. Id. "Some serious diseases in small children, such as meningitis caused by an inva-
sive type of Hemophilus or the meningococcus often suggest the need for prophylactic use of
antibiotics in schoolmates as well as household contacts." Id. at 128.
111. An example of a situation where a patient cannot be seen may include a highly com-
municable infectious disease where the patient has been previously exposed to a carrier and
would potentially infect other members of society if they leave there home. On the contrary,
not being able to get into the physician for work reasons or because the office is too busy, are
not reasons under this provision.
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scribed when a bacterial infection is diagnosed," 3 the physician in
her professional judgment can certify"4 that an antibiotic is necessary to pre-
vent the development of a complicated infection,"' or the patient is high risk for
developing an infection."6
Broad spectrum antibiotics" 7 should only be prescribed when the physi-
cian physically diagnoses a bacterial infection"8 and the patient is high risk for
developing complications from the infection," 9 or when the patient has already
concluded a narrow spectrum antibiotic regimen without improvement and the
physician performs culture and sensitivity test to harmonize antibiotic selec-
113. The advisory committee, consisting of experts in health care, such as physicians, phar-
macists, nurse practitioners, and infectious disease specialists, will assist the legislators in
enacting guidelines to accompany this Act. The advisory committee as a diverse array of health
care participants will also be responsible to assess whether a violation has occurred. For exam-
ple, a bacterial diagnosis may consist of actually taking a culture and sensitivity test or if
patient presents with tell tale signs and symptoms of bacterial infection.
114. See the certification procedure as outlined in text. Also, by utilizing a professional
judgment standard, we leave a certain degree of prescribing autonomy with the physician and
aid the arbitration board in determining if the standard of care performed was appropriate and
reasonable according to the standards established as guidelines.
115. See LEVY, supra note 10, at 127. "A common prophylactic use of antibiotics is to
prevent infection in patients who have had disease of the valves of the heart or have a heart
murmur." Id. "The latter indicates some change in the normal functioning of the heart that may
make them more susceptible to bacterial infections." Id. Also, following tooth extraction that
might cause transient passage of bacteria from the mouth into the bloodstream. Id. "Antibiotics
cannot prevent bacteria from entering the bloodstream, they can prevent them from 'setting up
shop."' Id. Antibiotics are not recommended for "clean" operations except where the rare
chance of infection could produce drastic consequences, such as in heart surgery. Id.
116. Id. at 126. "In a sick infant suffering from fever and possible dehydration and hav-
ing little body resilience, the high probability of bacterial infection warrants the use of antibi-
otics immediately and for the sustained period of the illness." Id. "In this case, early use of
medications can be truly life-saving, but clinicians still should utilize culture and susceptibili-
ty testing to confirm that the right drug had been started." Id. In addition, an elderly, very sick
patient with high fever and other signs of obvious infection is presumed to have a bacterial
infection, therefore, after culturing possible sites of infection, antibiotics are begun. Id.
"However, the same decision is not appropriate for an otherwise healthy, young adult who suf-
fers from symptoms attributable to a suspected viral illness." Id. at 127.
117. A lengthy discussion on the names of medications deemed narrow spectrum and broad
spectrum is inappropriate for this article. However, it is important to note that the narrow spec-
trum agents have selective specificity and are usually less expensive, whereas broad spectrum
antibiotic are the newer agents, oftentimes adaptations of the older agents which have a broad
range of attack on various bacteria. The broad spectrum agents can cost patients hundreds of
dollars whereas the older agents usually run less than twenty dollars. Michael A. Misocky,
Registered Pharmacist.
118. See supra note 116, for an example of diagnosing without the aid of culture and sen-
sitivity tests.
119. See supra notes 107-118, and accompanying text. Other factors include age of patient,
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tion.20 Another exception might be allowed where the patient has shown either
resistance or an allergic reaction to the recommended narrow spectrum agents.'2 '
Any second course of broad spectrum therapy for the same ailment
should only be prescribed by, or after consultation with, an infectious disease spe-
cialist,'22 or where the treating physician performs culture and sensitivity test and
certifies that the selected agent was appropriate.'23
The focus of regulatory action in the community will decrease the num-
ber of prescriptions phoned in without an actual office visit. This will enable a
physician to physically observe the patient and provides an excellent opportunity
for communication among health care participants. Regulations should aim to
force both the physician and patient to undergo certain checkpoints before initiat-
ing care to ensure that proper treatment is rendered.
The regulatory goal in the hospital atmosphere is to decrease the trans-
mission rate of resistant bacteria. The methodology proposed in this article pro-
vides a mechanism to facilitate aseptic techniques to decrease the risk of patients
developing a complicated infection.'24 Since hospitals are close quartered institu-
120. See LEVY, supra note 10, at 120. The author comments on the culture and sensitivi-
ty process: "physicians obtain cultures and perform tests on different areas of the body.. .In the
presence of a fever and soreness of the throat or difficulty swallowing, a physician may want
to obtain a swab of the throat and culture it to check for a bacterial culprit, such as streptococ-
cus, which causes strep throat." Id. "Initially, a simple test can be done in the office... the spu-
tum sample is smeared on a glass slide that is stained for bacteria, namely by the Gram stain."
Id. at 121. In addition, all clinical specimens should go to a bacteriology laboratory where they
are put into culture systems that allow growth of any microorganisms present. Id. at 122. The
specimens are cultured onto a special gelatin medium in round plastic dishes. Id. If the bacte-
riologist finds disease-causing bacteria in these samples, the microorganism is then tested for
susceptibility to antibiotics. Id at 123.
121. Id. Before our present-day problem with antibiotic resistance, simple identification
of the type of bacteria causing the disease would have been enough to tell the physician which
antibiotic to use. Id. Nowadays we must also determine which antibiotic is likely to be suc-
cessful. Id. "The physician must always make a choice of antibiotic based on not only the sus-
ceptibility results, but also from the knowledge of possible allergies of the patient. Id. at 124.
The physician should also assess the cost of medications which are effective. Id. at 125.
122. See North supra note 105, at 15 Suppl A:3-1 1. The author notes that the guidelines
established include the requirement that drugs which have been used "excessively or inappro-
priately in the past, are now only dispensed after consultation with an infectious disease spe-
cialist." Id.
123. The certification procedure as previously outlined in text, should include the culture
and sensitivity results for accuracy purposes.
124. Complicated infection as defined by reasonably prudent infectious disease specialist.
The risks associated with a hospital infection are greater because of the susceptibility of the
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tions, they serve as a breeding ground for bacteria.'25 As a result, by combining a
germ free operating environment 26 with a restricted antibiotic protocol,'27 hospi-
tals can control the emergence of antibiotic resistance.
Enforcing the regulations proposed in this article would be a daunting
task, but any such obstacles are certainly surmountable. 2 Enforcement could be
achieved by performing annual audits of physician and pharmacy records and, if
necessary, imposing monetary penalties and/or suspending or revoking licenses.
125. Hospitals have a diverse patient population, each with their own unique set of prob-
lem and accompanying strains of bacteria. The typical hospital patient may be exposed to a
wide variety of antibiotics, thus increasing the chances for resistant bacteria to spread via com-
mon carrier throughout the hospital.
126. The above notes and recommendations for the community apply with equal force in
the hospital environment. However, this would be an excellent time to present recommenda-
tions of the Hospital Infection Control Practices Advisory Committee (HICPAC) for prevent-
ing the spread of Vancomycin resistance. See Recommendations for Preventing the Spread of
Vancomycin Resistance,44 MMWR 1, Sep. 22, 1995. The recommendations include: prudent
vancomycin use by clinicians and immediate implementation of appropriate infection-control
measures to prevent person-to-person transmission of vancomycin resistant enterococci
(VRE). Id. at 8. The guidelines for preventing the patient-to-patient transmission of VRE:
1. Place VRE infected or colonized patients in private rooms or in the same room
as other VRE infected patients.
2. Wear gloves when entering the room of a VRE infected patient because VRE
can extensively contaminate such an environment.
3. Wear a gown when entering a VRE infected patient's room if a) substantial
contact with the patient or environmental surfaces is anticipated,
b) if the patient is incontinent, c) if the patient has had an ileostomy or
colostomy, has diarrhea or wound drainage.
4. Remove gloves and gown before leaving patient's room and immediately wash
with a antiseptic soap or waterless antiseptic agent.
5. Ensure that after glove and gown removal and handwashing, clothing and
handsdo not contact environmental surfaces in the patient's room.
127. Id. Guidelines for appropriate use:
I. Treatment of serious infections caused by beta-lactam resistant gram pos-
itive organisms.
2. For treatment of infections caused by gram-positive microorganisms in
patients who have serious allergies to beta-lactam antibiotics.
3. When antibiotic associated colitis fails to respond to metronidazole
therapy or is severe or potentially life-threatening.
4. Prophylaxis, as recommended by the American Heart Association, for
endocarditis following certain procedures for patients at high-risk for
endocarditis.
5. Prophylaxis for major surgical procedures involving implantation of pros-
thetic materials at institutions with a high rate of infections caused by
MRSA. Prophylaxis should be discontinued after a maximum of two
doses.
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Pharmacists could be the first line of defense in an enforcement model.
They could be required to report violations if, after consultation with the pre-
scribing physician and patient, they can verify violations to the appropriate
agency responsible for enforcement. '29 Moreover, pharmacists should be empow-
ered to refuse to fill prescriptions when doing so would be a violation of applica-
ble regulations. 3
Third party payers also have a role to play in enforcement. 3 ' Such enti-
ties could be required to initiate and maintain a drug utilization review program
aimed at restricting inappropriate antibiotic use. Third party payers could induce
compliance with their review programs by utilizing monetary incentives or
restrictions with both patients and physicians. Third party payers could also be
trol of implementation in the hands of the states, much like the EPA has done with various reg-
ulations, you ensure that state sovereignty is not infringed upon while necessitating the a uni-
form approach to the problem. Imposing various monetary fines and/or suspension/revocation
of licenses will coerce changes among practitioner's prescribing habits. The physician will be
served with a wake up call to acknowledge to existence of a pending epidemic. The audits of
physician and pharmacy records already have been conducted by the State Boards of Pharmacy
and Medicine concerning other violations of state/federal laws.
129. The certification procedure as described above with apply with equal merit here. The
pharmacist may be supplied with forms to be filled out when a violation occurs. The proper
investigation can then ensue. The certification should provide the nature of the violation and
include any appropriate discussions with the patient and/or physician. The pharmacist cur-
rently serves as gatekeeper in other overlapping areas of medicine and the law. As a drug ther-
apy expert, this power is not wrongly bestowed.
130. A pharmacist has the ability to refuse to fill a prescription which, in their professional
judgment is inappropriate or illegitimate. By incorporating legal regulations on antibiotic pre-
scribing, this will provide additional backing to enable the pharmacist to provide quality ther-
apeutic care in an area in great need of rehabilitation. See generally, C. Klein & J. Dasta,
Efforts of Pharmacy To Reduce Antibiotic Resistance, NEW HORIZ, Aug. 1996. The authors
note that pharmacists have an integral role in the care of patients with infections. Id.
Antibiotics continue to be among the most commonly prescribed drugs. Id. The authors note
that numerous studies point to inappropriate antibiotic use and resultant selective pressure on
antimicrobial resistance. Id. The pharmacist can impact this prescribing by assuring optimal
pharmacotherapy specific for the organism and associated disease. Id. Finally, the authors note
that future research is needed to determine the optimal method for preventing resistance, but
add that a multidisciplinary approach is suggested. Id.
131. Likewise, in order to properly control the conduct of both consumers and physicians,
an economic remedy from third party insurance companies, if properly administered, can serve
as a great incentive. A patient already has seen the impacts of managed care. The patient is
usually restricted on whom they may seek care or face increased out-of-pocket expenses.
Likewise, when faced with a therapeutically beneficial decision to forego an expensive antibi-
otic for a less expensive one, the decision may be quite easy if a patient is forced to bear the
costs of an inappropriate antibiotic. In addition, physicians rely heavily on insurance compa-
nies for payment of services rendered. It would be conducive to their profit margin to abide by
the regulations when faced with the imposition of monetary penalties for inappropriate pre-
scribing of antibiotics. The average third party payer will face little or no additional
cost to implement an additional therapeutic intervention onto their existing DUR programs.
The money saved as a result will surely pay for itself, and the consumer, who will be better off
medically, may also reap an economic kickback in the form of reduced premiums.
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authorized to conduct audits of pharmacies and physicians to assist them in com-
plying with applicable regulations. They could also be permitted to establish a
payment arrangement where the payer can withhold payment for services ren-
dered in violation of applicable regulations. Such payment disputes could be
handled by an informal "arbitration board"'32 established by the appropriate
enforcement agency.
Although the foregoing proposal is only a starting point for complex leg-
islation, the proposal can serve as a solid foundation upon which legislators can
build a comprehensive regulatory action. For example, the proposal fails to men-
tion drug manufacturers. However, potential legislation including the drug man-
ufacturers may include a tax subsidy for the development of new antibiotics,' a
limitation placed on free samples to be distributed to physicians,'" and a possi-
132. The arbitration board shall be established in the form of a judiciary to preside over
conflicting views among consumers, providers, and payers resulting from these regulations.
As experts in the health care arena, they will be able to properly convey their knowledge to the
parties, and make a decision which is based in the interests of public health.
133. See Horvitz, supra note 22, at 5. "[T]he congressional Office of Technology and
Assessment (which recently was eliminated by Congress) issued a report calling on the gov-
ernment to provide pharmaceutical companies with tax incentives to encourage research on
new drugs. But... no action has been taken to institute its recommendations." Id.
134. The current restraints on drug samples are not restraints at all, but merely procedur-
al requirements. See 21 U.S.C.A. § 353 (d) which states:
(2)(A) The manufacturer or authorized distributor of record of a drug subject to sub-
section (b) of this section may, in accordance with this paragraph, distribute drug
samples by mail or common carrier to practitioners licensed, to prescribe such drugs
or, at the request of a licensed practitioner to pharmacies of hospitals or other health
care entities. Such a distribution of drug samples may only be made-
(i) in response to a written request for drug samples made on a form which
meets the (B), and
(ii) under a system which requires the recipient of the drug sample to exe-
cute a written receip for the drug sample upon its delivery and the return
of the receipt to the manufacturer or authorized distributor of record.
(B) A written request for a drug sample required by subparagraph (A) (I) shall contain-
(i)the name, address, professional designation, and signature of practitioner
making the request,
(ii) the identity of the drug sample requested and the quantity requested,
(iii) the name of the manufacturer of the drug sample requested, and
(iv) the date of the request.
21 U.S.C. § 353 (d) (1995). A better approach would be to limit the maximum number of drug
samples which can be distributed. Also, restricting samples of new broad spectrum antibiotics
to physicians who can document the therapeutic need for such agent would prove more ben-
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ble accelerated approval time for antibiotics which can be used on a limited basis
in emergency situations. " Any law ultimately enacted to combat the problem of
antibiotic resistance should strive for a symbiotic relationship between the regu-
latory process and our health care system.' The proposal includes a communi-
cation ingredient, as well as, an enforcement mechanism to launch an effective
attack on the spread of infectious disease.'37 Although the proposal tailors to a
health and safety objective, hurdles still need to be crossed and obstacles cleared
to ease the rough terrain that patients, health practitioners, and industry may res-
urrect. 3 '
VII. PROBABLE OBJECTIONS
The regulatory process rarely finds favor with all whom it affects. In this
regard, arguments against the proposal will arise from patients, providers, and
drug manufacturers. 3 9 Patients will likely object because the regulations may
encroach on their perceived wellness.'1 A patient will have a difficult time un-
derstanding "no" and therefore attempt to seek out another provider to obtain the
For example, pharmacists have suggested that because a broad spectrum antibiotic is so expen-
sive, patients will be less likely to get a full prescription and rely on the sample quantity
instead. This practice yields harmful results and only aggravates the resistance problem
because the bacteria will be able to view the antibiotic without being terminated. Telephone
interview with Michael Dennis, Registered Pharmacist ( Jan. 22, 1997).
135. See generally, Accelerated approval with restricted access could be one option for han-
dling emerging antibiotic resistance, F-D-C REPORTS PRESCRIPTIONPHARMACEUTICALS AND
BIOTECHNOLOGY, July 29, 1996. The FDA Office of Drug Evaluation reports that making
antibiotics a class drug or controlled substance would be another approach. Id. This approach
would be consistent with the high psychological abuse potential of antibiotics. Id.
136. The answer to the antibiotic resistance epidemic lies in the ability of government and
industry to cooperate in an effort to stop the spread of infectious diseases. See generally
Joshua Lederberg, Infection Emergent, JAMA, Jan. 17, 1996 (noting that there is a need for a
government-industry cooperative to respond quickly in the event of a pandemic).
137. The existing legislation in Ohio provides a DUR (drug utilization review) mechanism
for claims submitted to Department of Human Services, see supra note 86, but only "recom-
mends" or "reminds" the practitioner of therapeutic guidelines, thus containing a communica-
tion ingredient but lacking an enforcement mechanism. See supra notes 86-87 and accompa-
nying text. Likewise, the public health laws and drug laws of Ohio contain the necessary
enforcement ingredient for violations but lack the communication which is essential to com-
pliance. See supra notes 96-97 and accompanying text. The proposal in this article combines
the two essential ingredients into one complex remedy aimed at alleviating the strain of antibi-
otic resistance.
138. For a general discussion on the problems associated with imposing regulations in the
health care field, see infra notes 140-163, and accompanying text.
139. See infra notes 140-163, and accompanying text.
140. See Meyer, supra note 41. "Nearly one-fourth of Americans misuse antibiotics-and
that's one reason meningitis, tuberculosis, and other diseases medicine once felled are now
more virulent than ever." Id. "70 percent of patients surveyed asked their doctors for antibi-
otics to treat viruses, against which the drugs are useless." Id. See also Mainous et al., supra
note 51, at 357: "Even though there is no cure for the common cold, physicians may still pre-
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antibiotics.'' However, the regulatory proposal seeks to impose uniform restric-
tions on all providers which will diminish doctor shopping among patients.
4 -2
Furthermore, patients may not understand that sacrificing their desires now will
ensure the future health of our nation.'' This concern will hopefully be addressed
by the integrity underlying the patient/physician relationship.1
A typical patient focuses on the isolation of an event without taking into
account the aggregate effects.' 5 For example a patient response might yield, " I
am only one person, how could I possibly cause an epidemic?" This common
thought process involves the problem of externalities, where an individual seeks
to minimize internal costs by allocating them to the entire population.' 6 For exam-
scribe antimicrobial agents, believing that patients expect to receive them." Id.
141. Id. "Physicians may feel the failure to prescribe an antibiotic will result in a dissatis-
fied patient who will seek care elsewhere. Thus, the seemingly benign act of prescribing an
antibiotic such as amoxicillin for a cold does little or no physical harm to the patient and keeps
the practice economically viable." Id. See also Hamm, et al., supra note 24 at 56. As a result
of a patient expectation study, the author concluded that "Sixty-five percent of the 113 patients
with respiratory infection expected antibiotics." Id.
142. For a discussion on why there is less bacterial resistance seen among patients in
Canada, see Nichols, supra note 46, at 40. The author notes that "drug resistance in Canada is
less of a problem so far than in the United States.. .due to differences in U.S. and Canadian
health-care systems." Id. at 42. "Because most medical services in Canada are publicly fund-
ed, hospitals, and to lesser extent community-based physicians, face .more stringent limitations
than most of their American counterparts in prescribing expensive antibiotics." Id.
143. See Cash, supra note 48, at 181. "We are now paying the price for our decades of
awe of the medical profession, for our reluctance to leave a doctor's office without a prescrip-
tion, and, conversely, for our dumb acceptance of whatever the mighty doctor orders, for our
impatience with the natural course of infection, for our senseless squandering of antibiotics,
one of man's most precious resources." Id.
144. In order for a regulatory program to be effective, communication among health care
providers on the issue of antibiotic resistance is essential to a successful implementation.
"When you tell a patient 45 times a day that they don't need an antibiotic for their cold, this
statement can get pretty old after a while." Telephone interview with Dr. Todd Zacour, Zacour
Family Practice in Clinton, Ohio (November 10, 1996). The physician did note, however, that
some patients do understand and are glad if they can save a few extra bucks on medicine. Id.
Furthermore, it is necessary to address a patient's faith in their physician. A patient has main-
tained a "doctor knows best" attitude for many years and have taken antibiotics even when they
don't want them, therefore, it is likely that patients, over time, will yield to the physician's best
advice on whether an antibiotic is warranted.
145. See Novitt-Moreno, supra note 45, at 6. The author comments on an individual's con-
tribution to the external problem of antibiotic resistance. Id. "Every time we take an unneces-
sary antibiotic to treat a viral infection, we give local bacteria another peak at one of our antibi-
otic weapons. And we give them another shot at becoming resistant. So the next time you go
to your doctor's office, don't automatically expect a prescription for antibiotics. Your doctor
may be saving his weapon for another battle." Id. at 8.
146. For a general discussion of economics and the law, see RICHARD POSNER, EcoMONIc
ANALYSIS OF LAW, 59 (1977). The author discusses how economics play a vital role in the
development of law. Id. For example, if no liability is imposed on an injurer, an incentive exists
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pie, patients are less likely to take precautionary measures when the ill-effects are
dispersed among all health care participants. However, since the proposed regu-
lation encompasses a monetary stimulus, individual patients will find the costs
associated with antibiotic misuse hitting closer to home.147 Moreover, the federal
government has regulated individual conduct in the past when it presented a
national concern analyzing the aggregate effects.1 41 Therefore, it is necessary in
our proposal to regulate individual conduct when the cumulative effects may
jeopardize the health of our nation. 149
Although many physicians would acknowledge the existence of a prob-
lem, few will take the blame. Thus, a physician will express discontent with a reg-
ulatory proposal. After approximately twelve years of post high school education,
physicians may have a valid reason to disapprove of yet another infringement on
their prescribing autonomy."' Along these lines, our nation requires a demanding
medical education and subsequently the granting of a license before entrusting
internalized or placed on the victim. Id. On the other hand, if strict liability is imposed on injur-
er, little incentive exists for the victim to take precautionary measures. Id. The costs are then
said to be externalized or distributed among greater numbers of people. Id.
147. Id. In the health care arena, individual patients with insurance, who receive unwar-
ranted antibiotics, externalize their costs by raising insurance premiums for all members of a
group. Thus, implementing monetary incentives to restrict antibiotic misuse, will help cen-
tralize unnecessary costs back to the patient.
148. See e.g., Wickard v. Filbum, 317 U.S. 111 (1942) (holding that Congress may proper-
ly have considered that the individual farmer's own contribution to the demand for wheat may
be trivial by itself is not enough to remove it from the scope of federal regulation where, as
here, his contribution taken together with those similarly situated, is far from trivial).
149. For a description of how bad things could get without a halt on the overuse of antibi-
otics, see Nichols, supra note 46. The author notes:
How bad could it get? Terrifyingly bad, if the rapidly reproducing and mutating
microbes continue to find ways of outfoxing medicine's battery of antibiotics.
There would be nothing to stop some children's ear infections, for instance, from turn-
ing into life-threatening meningitis, and cases of pneumonia that are now routinely
treated could instead become routinely fatal. Already, drug resistance is plaguing
North American hospitals and the new bugs are making it harder for doctors to treat
once easy-to-cure infections.
Id. at 40. The author adds that "if the number and variety of drug-resistant bacteria continue
to proliferate, running out of antibiotics could become a real possibility." Id. (quoting Dr.
Stephen Vas, a University of Toronto microbiologist).
150. Although many physicians who underscore the nature of the problem will likely object
to an infringement on their prescribing autonomy, other physicians will welcome an adminis-
trative resolution to the problem. For additional commentary on why legal regulations are
needed, see Nichols, supra note 144. The author asks "Do we need t: v,, some kind of con-
trols on what doctor's can prescribe?" Id. at 40. The author remarks that c,, 1trols "would be
something that doctors and their patients, would be certain to resent.... But it could be just one
of the measures up for consideration if the microbial world continues to make progress in its
relentless war with modern medicine." Id. Nichols comments on the prescribing mentality of
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physicians with the health and safety of our people.' As previously mentioned,
physician prescribing autonomy is not absolute.'52 In fact, the field of medicine is
heavily regulated to promote the wellness of society."3 Furthermore, some physi-
cians may leap at an opportunity to "just say no" without fear of compromising
patient satisfaction.'"' As a result, regulations are necessary to halt the inappropri-
ate use of antibiotics and to preserve the integrity of our nation's health care sys-
tem. 1
55
Finally, after billions of dollars in research and development costs, drug
manufacturers will most likely lobby against a regulatory program.'56 Since it
takes nearly fourteen years for a drug to reach the market, the manufacturers
adamantly promote the sale of new medications in order to recoup costs.
57
Additionally, they will complain that the imposition of regulations will result in a
"catch-22" situation.' 8 They will assert that restricting the manufacturers ability
to recoup costs will only accelerate the problem by forcing a corresponding
decrease in the development of new antibiotics.'59 However, as this article recom-
some physicians: "Well, it can't do any harm-might as well start them on antibiotics.... Now
we are seeing the consequences of this." Id. at 42. "Experts say that prescribing antibiotics has
become so automatic that many doctors do not even bother to determine first if an illness is
viral-in which case antibiotics are ineffective-or bacterial in origin." Id.
151. See generally OHIO REVISED CODE Physician license application requirements. Ohio
Revised Code Sec. 4730 (Banks-Baldwin 1996).
152. See generally Ohio Revised Code, supra note 74 and accompanying text for a discus-
sion on the prescribing limitations on physicians.
153. Id.
154. See generally Hamm et al., supra note 24. The author comments on a patient's
absolute insistence on antibiotic treatment. Id. The author highlights a patient's willingness to
seek out another provider, who will supply them with their necessary fix. Id.
155. Id. "Today's crisis over drug resistance is the product of a competition that has raged
for the past half-century between disease causing bacteria and the modem, man-made agents
designed to combat them." Id. The author remarks on the current problem: "What is clear is
that widespread overuse of antibiotics provides an ideal breeding ground for mutant bacteria
that can threaten human life: the more antibiotics are used, the more opportunity bacteria have
to develop invulnerability-and pass that talent on to other bugs." Id.
156. See Donald A. Goldmann, et al., Strategies to Prevent and Control the Emergence and
Spread of Antimicrobial- resistant Microorganisms in Hospitals: a Challenge to Hospital
Leadership, JAMA, Jan. 17, 1996, at 234. "Faced with this erosion in the efficacy of even the
newest antimicrobials, clinicians have relied increasingly on the ability of the pharmaceutical
industry to develop novel agents. However, the costs of discovering, developing, testing, and
approving antimicrobials continue to escalate while the hazards of unexpected toxicity and
clinical failure remain." Id. at 235.
157. For a discussion with a sales representative for a drug company, see infra note 159.
158. See Goldmann, et al, supra note 158 at 235. Moreover, with rapid emergence of resis-
tance, the incentive to develop new antimicrobials diminishes as the projected useful life span
of these agents declines. The bottom line is that industry is finding it increasingly difficult to
keep pace with antimicrobial resistance..." Id. See also Horvitz, supra note 22 at 38 . "Major
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mends, the legislature may include a tax subsidy or accelerated approval provi-
sion to counteract the monetary losses attributed to the regulations.110
Many taxpayers will express disapproval because regulatory agencies
need funding to be successful.' A typical question would be, "How can we
afford to pay for this?" However, how can we afford not to?'62 In reality, the reg-
son, not surprisingly, is economics. 'Drug companies concentrated on cardiovasculars and
abandoned infectious diseases. Patients given cardiovascular medications, such as beta block-
ers will take it for the rest of their lives while people with infections will only need a drug for
the duration of their illness, usually no longer than a week or two."' Id.
159. Telephone Interview with Dennis Lee, Sales Representative, Zeneca Pharmaceuticals
in Akron, Ohio, (Feb. 10, 1997). Mr. Lee states that "we are at a disadvantage starting out,
because after millions of dollars in research and development costs, and a number of years
invested, it is difficult to explain why the medicine costs so much." Id. Mr. Lee adds, "when
calling on a physician's office, we promote our product as the newest and best available treat-
ment for a particular disease, we will leave drug samples, and generally, we just try to push the
sale of our product." Id. The drug manufacturers want to recoup research and development
costs within the first 2-3 years after it reaches the market because the possibility new products
will come out and take control of the market or in the alternative a patent will run out and a
generic drug will be available. It is common knowledge among members in the drug industry
that profits directly correspond with the number of prescription that are being written for your
product. In the coming years, this poses an incredible obstacle to the imposition of regulations
on antibiotic prescribing, however, given the right monetary incentives, the price for health can
usually be achieved. See Sheridan, supra note 7 at 41. The author comments on the clout of
pharmaceutical companies:
Scientists have been aware for 20 years that bacteria have been breaching the
bulwarks. Long before the WHO report, individuals and interested bodies were
calling for tighter controls on the dispensing of antibiotics But anyone seeking
change in this area is also tangling with the marketing might, money, and global
power of the pharmaceutical companies for whom antibiotics have been a
license to print money.
Id. "[W]hen the U.S. National Institutes of Health attempted a global initiative in the mid-
1980's designed to stop antibiotic misuse, their work was thwarted by a number of major phar-
maceutical companies able to put pressure on the White House." Id.
160. Despite the relatively short half-life of antibiotics because of resistance, the drug com-
panies are still pursuing the development of new entities. See Industry Focuses on Superbugs,
PHARMACEUTICAL BUSINESS NEWS, Nov. 21, 1996. The authors notes generally that bacteria
which are immune to drug therapy is creating a challenge for the pharmaceutical industry and
the WHO (World Health Organization). Id. The development of a drug able to fight the resis-
tant strains could be worth a least $1 billion dollars in annual sales for the manufacturer. Id.
161. However, with time, the cost of regulation will more than pay for itself in health care
savings, due to a decline in the rate of infectious diseases.
162. See Sheridan, supra note 7. The author states that "You could of course be highly
socially responsible and/or lucky and manage to avoid antibiotics all your life. But you could
stillbecome ill with disease caused by a super-bug merely through breathing the same air in
theaters and shopping centers as people who have developed drug-resistant bacteria. No one
is safe anymore, says WHO: 'We are standing on the brink of a global crisis in infectious dis-
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ulatory proposal, if properly carried out, will add funds to the treasury due to a
sharp decline in the cost of treatment for infectious diseases.
63
VIII. CONCLUSION
As we move into the next millennium, where will we stand in the battle
against bacteria? 'The answer to this question revolves around either putting
things off until a national crisis occurs or meeting antibiotic resistance head on to
thwart the progression of the inevitable. This article sets forth guidelines for reg-
ulatory action to allow our lawmakers to formulate a comprehensive attack on
antibiotic resistance. If properly enforced, this proposal harnesses the ability to
lower health care costs without compromising optimal therapeutics in the treat-
ment of infectious diseases.
As the last line of defense falls prey to bacteria's uncanny ability to resist
destruction, we are faced with a pending epidemic to which there may be no cure.
The lack of new antibiotics in the near future, the misuse and overuse of current
antibiotics, and society's nonchalant attiude toward antibiotic resistance sets the
stage for the emergence of a "superbug" dictator.
Antibiotics still remain a vital instrumentality in the treatment of infec-
tious diseases and this article in no way suggests we should abandon this method
of treatment. However, we are at a time where overkill becomes more than a
descriptive term. The more we become accustomed to the "miracle drug" and its
plethora of benefits, the sooner we will find ourselves caught in the crossfire of
antibiotic resistance. Although a voluntary remedial effort is ideal, the competi-
tive nature of society mandates that a restrictive regime is necessary to keep a few
bad apples from infecting the whole tree.
The regulatory proposal encompasses the necessary schematics to attack
the interposing problem on three fronts. The proposal will allay public miscon-
ception about the power of antibiotics. In addition, a uniform approach will
restrict physician's polypharmacy tendencies and hinder the "revolving door"
treatment method. Finally, drug manufacturers will applaud the potential profit
margin increase seen as a result of restricting the use of highly-susceptible antibi-
otics.
163. See Horvitz, supra note 22, at 38. "During the last 12 years, the rate of mortality from
infectious diseases has risen 58 percent, becoming the third-leading killer of Americans.
Furthermore, the Centers for Disease Control and Prevention, or CDC, estimates that more
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A possible approach for complex legislation might include a trial regula-
tory period for an isolated class of persons. For example, a state may show a com-
pelling state interest exists in maintaining the health of Medicaid patients and ini-
tiate the regulatory proposal in a limited fashion. Then, after a significant health
benefit is actuated, the regulations may be broadened to include the entire
patient/physician population.
This article has recognized the existence of a significant health threat and
the availability of a legal remedy to reduce the threat of antibiotic resistance. The
Black Death tormented Europe for nearly three centuries before a legal remedy
was introduced. It is time to heed the message dictated by our predecessor's mis-
takes and halt the progression of the "superbug" epidemic. By initiating a regu-
latory action in the infectious disease arena, we reaffirm the strength of our demo-
cratic processes and preserve the vitality of our nation's health care system.
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